<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Clinical applications of thrombopoietic growth factors</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Clinical applications of thrombopoietic growth factors</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Clinical applications of thrombopoietic growth factors</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David J Kuter, MD, DPhil</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lawrence LK Leung, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer S Tirnauer, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 18, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The use of hematopoietic growth factors has markedly changed the practice of medicine. Erythroid growth factors (eg, erythropoietin) and myeloid growth factors (eg, granulocyte colony-stimulating factor) have allowed the specific stimulation of the production of erythrocytes and neutrophils, respectively. (See  <a class="medical medical_review" href="/d/html/8383.html" rel="external">"Introduction to recombinant hematopoietic growth factors"</a>.)</p><p>With the discovery of thrombopoietin (TPO) and the development of a variety of peptide and non-peptide TPO receptor agonists (TPO-RAs), clinically effective thrombopoietic growth factors are now part of the clinical armamentarium. This topic review will discuss the thrombopoietic growth factors that have been developed, their activity in preclinical models, and the available clinical studies. The biology of TPO and its related disorders are discussed separately. (See  <a class="medical medical_review" href="/d/html/6673.html" rel="external">"Biology and physiology of thrombopoietin"</a>.)</p><p class="headingAnchor" id="H6974285"><span class="h1">CLINICAL UTILITY</span><span class="headingEndMark"> — </span>The potential clinical applications of thrombopoietic growth factors are suggested by analyzing the use of platelet transfusions (<a class="graphic graphic_figure graphicRef77264" href="/d/graphic/77264.html" rel="external">figure 1</a>). (See  <a class="medical medical_review" href="/d/html/7918.html" rel="external">"Platelet transfusion: Indications, ordering, and associated risks", section on 'Indications for platelet transfusion'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Three TPO receptor agonists (<a class="drug drug_general" data-topicid="9493" href="/d/drug information/9493.html" rel="external">romiplostim</a>, <a class="drug drug_general" data-topicid="9051" href="/d/drug information/9051.html" rel="external">eltrombopag</a>, <a class="drug drug_general" data-topicid="117929" href="/d/drug information/117929.html" rel="external">avatrombopag</a>) have been approved for the treatment of immune thrombocytopenia (ITP). (See  <a class="medical medical_review" href="/d/html/6678.html" rel="external">"Second-line and subsequent therapies for immune thrombocytopenia (ITP) in adults", section on 'TPO receptor agonists'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Two TPO receptor agonists (<a class="drug drug_general" data-topicid="9051" href="/d/drug information/9051.html" rel="external">eltrombopag</a> and <a class="drug drug_general" data-topicid="9493" href="/d/drug information/9493.html" rel="external">romiplostim</a> [Japan only]) have been approved for the treatment of aplastic anemia. (See  <a class="medical medical_review" href="/d/html/7158.html" rel="external">"Treatment of aplastic anemia in adults", section on 'Eltrombopag alone'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Two TPO receptor agonists (<a class="drug drug_general" data-topicid="117929" href="/d/drug information/117929.html" rel="external">avatrombopag</a> and <a class="drug drug_general" data-topicid="118602" href="/d/drug information/118602.html" rel="external">lusutrombopag</a>) have been approved for the treatment of thrombocytopenic patients with chronic liver disease about to undergo procedures.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The utility of these agents in myelodysplastic syndromes is discussed separately. (See  <a class="medical medical_review" href="/d/html/15776.html" rel="external">"Myelodysplastic syndromes/neoplasms (MDS): Management of hematologic complications in lower-risk MDS", section on 'Refractory bleeding'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There are numerous uses of these agents in other thrombocytopenic disorders. (See <a class="local">'Use of TPO receptor agonists'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Although interferon is no longer used to treat hepatitis C virus infection, one TPO receptor agonist (<a class="drug drug_general" data-topicid="9051" href="/d/drug information/9051.html" rel="external">eltrombopag</a>) was approved for the treatment of thrombocytopenia in patients with hepatitis C who are being treated with interferon. </p><p></p><p class="headingAnchor" id="H2"><span class="h1">THROMBOPOIETINS (C-MPL LIGANDS)</span><span class="headingEndMark"> — </span>A number of thrombopoietin (TPO) molecules have been developed [<a href="#rid1">1,2</a>]; they define a new and growing family of molecules called the thrombopoietin (or mpl ligand) family, based upon their common ability to bind and activate the TPO receptor, c-mpl [<a href="#rid3">3</a>] (<a class="graphic graphic_table graphicRef55953" href="/d/graphic/55953.html" rel="external">table 1</a>). These include the recombinant thrombopoietins and two different types of TPO receptor agonists: peptide TPO receptor agonists and non-peptide TPO receptor agonists [<a href="#rid4">4</a>]. These TPO receptor agonists are functional rather than structural TPO mimetics because they act as agonists for the TPO receptor but lack sequence homology to the TPO protein.</p><p>There have been two waves of development of the thrombopoietic growth factors.</p><p class="bulletIndent1"><span class="glyph">●</span>The first-generation molecules were recombinant thrombopoietins (eg, rHuTPO, PEG-rHuMGDF), only one of which, rHuTPO, was clinically developed; this therapy is only available in China. (See <a class="local">'Recombinant thrombopoietins'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The second-generation molecules are highly modified structures (eg, <a class="drug drug_general" data-topicid="9493" href="/d/drug information/9493.html" rel="external">romiplostim</a>, <a class="drug drug_general" data-topicid="9051" href="/d/drug information/9051.html" rel="external">eltrombopag</a>, <a class="drug drug_general" data-topicid="117929" href="/d/drug information/117929.html" rel="external">avatrombopag</a>, <a class="drug drug_general" data-topicid="118602" href="/d/drug information/118602.html" rel="external">lusutrombopag</a>, hetrombopag) that mimic the function of TPO. Three of these (romiplostim, eltrombopag, and avatrombopag) are approved by the US Food and Drug Administration (FDA) and are widely used to treat ITP [<a href="#rid5">5</a>]. Eltrombopag is also approved for the treatment of thrombocytopenia in hepatitis C patients receiving interferon. Eltrombopag and romiplostim (Japan only) are approved for the treatment of aplastic anemia. Avatrombopag and lusutrombopag are licensed for the treatment of thrombocytopenia in patients with liver disease undergoing surgical procedures [<a href="#rid6">6-8</a>]. Hetrombopag is under development in China for chemotherapy-induced thrombocytopenia. (See <a class="local">'Clinical utility'</a> above and <a class="local">'Non-peptide TPO receptor agonists'</a> below.) </p><p></p><p class="headingAnchor" id="H3"><span class="h2">Recombinant thrombopoietins</span><span class="headingEndMark"> — </span>Two recombinant thrombopoietins were subjected to intensive clinical investigation (<a class="graphic graphic_figure graphicRef58678" href="/d/graphic/58678.html" rel="external">figure 2</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Recombinant human thrombopoietin (rHuTPO) is a glycosylated molecule produced in Chinese hamster ovary (CHO) cells consisting of the full-length, native human amino acid sequence, which has a circulatory half-life of 20 to 40 hours. rHuTPO (TPIAO) is approved only in China for treatment of chemotherapy-induced thrombocytopenia and ITP [<a href="#rid9">9</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pegylated, recombinant megakaryocyte growth and development factor (PEG-rHuMGDF), a nonglycosylated, truncated molecule produced in <em>Escherichia coli</em>, is composed of the first 163 amino acids of the native molecule, chemically coupled to polyethylene glycol. This half of the native molecule is 50 percent similar to erythropoietin, contains the receptor-binding domain, but very little biologic activity in vivo due to the absence of the remaining, carbohydrate-rich portion of the native molecule that gives it a very short circulatory half-life. Addition of the polyethylene glycol moiety serves to replace the missing carbohydrate domain and stabilize the molecule in the circulation [<a href="#rid10">10</a>]. PEG-rHuMGDF has a half-life of 30 to 40 hours. Clinical development of this molecule was stopped because of the development of antibodies, leading to thrombocytopenia, in approximately 8 percent of individuals [<a href="#rid2">2,3,11-13</a>]. (See <a class="local">'Antibody formation'</a> below and  <a class="medical medical_review" href="/d/html/6673.html" rel="external">"Biology and physiology of thrombopoietin"</a>.)</p><p></p><p>Studies with both of these molecules in healthy people and primate models have demonstrated the general clinical effects of all the thrombopoietic growth factors [<a href="#rid4">4,5,14</a>]. After a single dose of rHuTPO or PEG-rHuMGDF, there is an increase in megakaryocyte size, number, and DNA ploidy followed by a dose-dependent increase in platelet count that begins on day 5, peaks at a mean of day 12, and returns to baseline by day 28 [<a href="#rid15">15,16</a>]. </p><p class="headingAnchor" id="H4"><span class="h2">Peptide TPO receptor agonists</span><span class="headingEndMark"> — </span>Peptide TPO receptor agonists are short peptide sequences, usually with no sequence homology with TPO, which bind and activate the TPO receptor. They were discovered by screening peptide "libraries" for sequences that activated the TPO receptor. One of these was a 14-amino acid peptide having no sequence homology with TPO, which was able to bind to and activate the TPO receptor, c-mpl [<a href="#rid17">17</a>]. Dimerization of this peptide increased its activity 10,000-fold, thereby making it as active as recombinant TPO.</p><p>A key attribute of all of the peptide TPO receptor agonists is the need for a structure that allows them to dimerize and activate the TPO receptor. These peptides have too short a half-life in the circulation to be clinically active. To enhance their circulatory half-life, peptides have been inserted into carrier proteins such as the immunoglobulin heavy chain and have marked clinical activity when administered subcutaneously or intravenously.</p><p class="headingAnchor" id="H5"><span class="h3">Romiplostim (Nplate, Romiplate)</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9493" href="/d/drug information/9493.html" rel="external">Romiplostim</a> (Nplate, Romiplate, AMG 531) is a "peptibody" composed of two disulfide-bonded human IgG1 kappa heavy chain constant regions (an Fc fragment), each of which is covalently bound at residue 228 with two identical peptide sequences linked via polyglycine (<a class="graphic graphic_figure graphicRef69951" href="/d/graphic/69951.html" rel="external">figure 3</a>) [<a href="#rid10">10</a>]. This agent increased the platelet count in healthy individuals [<a href="#rid18">18,19</a>] as well as in patients with immune thrombocytopenia (ITP) [<a href="#rid20">20-23</a>] and myelodysplastic syndrome [<a href="#rid24">24-26</a>]. Romiplostim has also been evaluated in patients with chemotherapy-induced thrombocytopenia [<a href="#rid27">27,28</a>], hepatitis C-related thrombocytopenia, thrombocytopenia prior to undergoing surgery [<a href="#rid29">29</a>], and aplastic anemia [<a href="#rid30">30</a>]. </p><p><a class="drug drug_general" data-topicid="9493" href="/d/drug information/9493.html" rel="external">Romiplostim</a> is FDA-approved for the treatment of ITP in adults and in children age one and above. It is administered weekly as a subcutaneous injection at a dose of 1 to 10 mcg/kg. (See  <a class="medical medical_review" href="/d/html/6678.html" rel="external">"Second-line and subsequent therapies for immune thrombocytopenia (ITP) in adults", section on 'TPO receptor agonists'</a>.) </p><p>It is also FDA-approved for radiation injury, based on animal studies. (See <a class="local">'Radiation injury'</a> below.)</p><p><a class="drug drug_general" data-topicid="9493" href="/d/drug information/9493.html" rel="external">Romiplostim</a> is approved in Japan for treatment of aplastic anemia [<a href="#rid30">30</a>]. (See  <a class="medical medical_review" href="/d/html/7158.html" rel="external">"Treatment of aplastic anemia in adults"</a>.)</p><p class="headingAnchor" id="H6"><span class="h2">Non-peptide TPO receptor agonists</span><span class="headingEndMark"> — </span>Non-peptide TPO receptor agonists were derived from small molecule screening techniques that uncovered a number of chemical structures that bound to and activated the TPO receptor. Structures such as the hydrazinonaphthalene compounds readily activate the TPO receptor [<a href="#rid31">31-34</a>]. Three of these are FDA approved for various thrombocytopenic disorders. One potential advantage they have over <a class="drug drug_general" data-topicid="9493" href="/d/drug information/9493.html" rel="external">romiplostim</a> is that they may be administered orally. All four bind to and activate the TPO receptor by a mechanism different from endogenous TPO, recombinant TPO, or romiplostim [<a href="#rid5">5</a>]. Their effect may be additive to that of TPO, and this may confer on them a second advantage over romiplostim.</p><p class="headingAnchor" id="H7"><span class="h3">Eltrombopag (Promacta, Revolade, SB497115)</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9051" href="/d/drug information/9051.html" rel="external">Eltrombopag</a> (Promacta, Revolade) has an acidic (COOH) group at one end, lipophilic (eg, methyl) groups at the other end, and a metal chelate group in the center that creates an orally available non-peptide TPO receptor agonist (<a class="graphic graphic_figure graphicRef79697" href="/d/graphic/79697.html" rel="external">figure 4</a>) [<a href="#rid35">35</a>]. It increases the platelet count in healthy individuals and in thrombocytopenic patients with ITP, hepatitis C, or aplastic anemia [<a href="#rid33">33,36-43</a>]. In one trial, it raised the nadir platelet count when administered to patients after non-myeloablative chemotherapy [<a href="#rid44">44</a>]. It is FDA-approved for the treatment of adults and children over one year of age with ITP, patients with hepatitis C-related thrombocytopenia who are being treated with interferon, patients with aplastic anemia who are unresponsive to immunosuppressive therapy, and adults and children over two years of age as the initial therapy for aplastic anemia in combination with immunosuppressive therapy. It is available as orally administered tablets of 12.5, 25, 50, 75, and 100 mg as well as 12.5 mg and 25 mg oral suspension; lower starting doses should be used in patients of Asian ancestry or with impaired liver function.</p><p class="headingAnchor" id="H3241288"><span class="h3">Avatrombopag (Doptelet, E5501, AKR-501, YM-477)</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="117929" href="/d/drug information/117929.html" rel="external">Avatrombopag</a> (Doptelet) is an orally-available non-peptide TPO receptor agonist (<a class="graphic graphic_figure graphicRef131219" href="/d/graphic/131219.html" rel="external">figure 5</a>). It is approximately threefold more potent than <a class="drug drug_general" data-topicid="9051" href="/d/drug information/9051.html" rel="external">eltrombopag</a> in raising the platelet count in healthy volunteers [<a href="#rid45">45</a>]. Unlike eltrombopag, it does not alter liver function tests or require any dietary restrictions [<a href="#rid46">46-48</a>]. It has been shown to raise platelet counts in individuals with immune thrombocytopenia (ITP) and chronic liver disease [<a href="#rid49">49-51</a>]. In a phase III trial, 227 individuals with liver disease who had platelet counts &lt;50,000/microL and required an invasive procedure were randomly assigned to receive avatrombopag or placebo daily for five days and assessed for the need for platelet transfusions up to seven days after procedure [<a href="#rid8">8</a>]. Avatrombopag increased the platelet count and reduced the need for transfusions (transfusions given in 12 to 34 percent of the avatrombopag group versus 62 to 77 percent of the placebo group). There was no difference in bleeding events, and no thrombotic events after close assessment of the portal vein system by ultrasound.</p><p>In a randomized trial in chronic ITP, <a class="drug drug_general" data-topicid="117929" href="/d/drug information/117929.html" rel="external">avatrombopag</a> was associated with a greater platelet count response (platelet count &gt;50,000/microL) than placebo (12.4 weeks versus 0 weeks with placebo) [<a href="#rid51">51</a>]. Responses occurred early with 65.6 percent of responses seen after eight days. Bleeding was also decreased and use of concomitant ITP medications reduced in those on avatrombopag.</p><p><a class="drug drug_general" data-topicid="117929" href="/d/drug information/117929.html" rel="external">Avatrombopag</a> is FDA approved for adults with chronic liver disease who are scheduled to undergo a procedure and those with chronic ITP who have had an insufficient response to a previous treatment. (See  <a class="medical medical_review" href="/d/html/13932.html" rel="external">"Hemostatic abnormalities in patients with liver disease", section on 'Invasive procedures'</a> and  <a class="medical medical_review" href="/d/html/6678.html" rel="external">"Second-line and subsequent therapies for immune thrombocytopenia (ITP) in adults", section on 'TPO receptor agonists'</a>.)</p><p class="headingAnchor" id="H182332705"><span class="h3">Lusutrombopag (Mulpleta)</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="118602" href="/d/drug information/118602.html" rel="external">Lusutrombopag</a> is another orally available non-peptide TPO receptor agonist akin to <a class="drug drug_general" data-topicid="9051" href="/d/drug information/9051.html" rel="external">eltrombopag</a> and <a class="drug drug_general" data-topicid="117929" href="/d/drug information/117929.html" rel="external">avatrombopag</a>. It is FDA approved to increase the platelet count in adults with chronic liver disease who are scheduled to undergo a procedure [<a href="#rid6">6,7</a>]. (See  <a class="medical medical_review" href="/d/html/13932.html" rel="external">"Hemostatic abnormalities in patients with liver disease", section on 'Invasive procedures'</a>.)</p><p class="headingAnchor" id="H3578766121"><span class="h3">Hetrombopag</span><span class="headingEndMark"> — </span>Hetrombopag is an orally available TPO receptor agonist available in China for ITP and severe aplastic anemia; it is also under evaluation for chemotherapy-induced thrombocytopenia [<a href="#rid52">52</a>].</p><p class="headingAnchor" id="H9"><span class="h1">OTHER MOLECULES WITH THROMBOPOIETIC ACTIVITY</span><span class="headingEndMark"> — </span>Since they are based on the only physiologically relevant platelet growth factor, thrombopoietin (TPO), the thrombopoietins have captured most of the attention. (See <a class="local">'Thrombopoietins (c-mpl ligands)'</a> above.)</p><p>However, several other molecules not related to thrombopoietin or its receptor can enhance platelet production. </p><p>Interleukins (IL)-3, IL-6, and IL-11 stimulate platelet production. </p><p>Only one (Oprelvekin; IL-11) was approved by the US Food and Drug Administration (FDA) for use in chemotherapy-associated thrombocytopenia; it was able to stimulate megakaryocyte growth and increase platelet production with a time course similar to that of thrombopoietin, in a mechanism independent of thrombopoietin release or synergism and is independent of the thrombopoietin receptor [<a href="#rid53">53,54</a>]. It modestly reduced chemotherapy-induced thrombocytopenia and the need for platelet transfusions, but it had significant side effects including fluid retention with dilutional anemia, peripheral edema, pleural effusions, and atrial arrhythmias [<a href="#rid5">5,55-59</a>]. Oprelvekin is no longer clinically available [<a href="#rid60">60</a>]. </p><p>IL-11 is probably not important for normal megakaryocytopoiesis, since elimination of the gene for the IL-11 receptor in mice produced no effect on the production of platelets or any other blood cell line [<a href="#rid61">61,62</a>]. </p><p class="headingAnchor" id="H18"><span class="h1">USE OF TPO RECEPTOR AGONISTS</span><span class="headingEndMark"> — </span>Thrombocytopenia is a common problem in many chronic hematologic conditions, ranging from aplastic anemia to drug-induced thrombocytopenia. It is anticipated that if adequate amounts of responsive bone marrow precursor cells are present, thrombopoietin (TPO) may be helpful in many of these patients. Extensive preclinical and clinical data provide guidance as to the settings in which the thrombopoietic growth factors may be useful [<a href="#rid5">5,63-65</a>]. </p><p>This section provides an overview of the thrombocytopenic conditions treated with these thrombopoietic growth factors with a focus on the current TPO receptor agonists but supported with the preclinical and early clinical data with the recombinant thrombopoietins.</p><p class="headingAnchor" id="H6974564"><span class="h2">Immune thrombocytopenia</span><span class="headingEndMark"> — </span>The finding that TPO levels in patients with immune thrombocytopenia (ITP) were not significantly elevated [<a href="#rid66">66,67</a>] and that most patients with ITP are not producing platelets at a maximal rate [<a href="#rid68">68,69</a>], suggests a potential benefit of TPO receptor agonists in this disorder.</p><p><a class="drug drug_general" data-topicid="9493" href="/d/drug information/9493.html" rel="external">Romiplostim</a>, <a class="drug drug_general" data-topicid="9051" href="/d/drug information/9051.html" rel="external">eltrombopag</a>, and <a class="drug drug_general" data-topicid="117929" href="/d/drug information/117929.html" rel="external">avatrombopag</a> are US Food and Drug Administration (FDA) approved for treating adults with ITP and have been found to be highly effective [<a href="#rid20">20-23,38,40</a>]. In general, over 80 percent of ITP patients treated with TPO receptor agonists attain a long-term rise in platelet count &gt;50,000/microL with reduced bleeding, increased quality of life, and minimal adverse effects (<a class="graphic graphic_table graphicRef55815" href="/d/graphic/55815.html" rel="external">table 2</a>) [<a href="#rid70">70</a>]. Their long-term use in patients with ITP has been found to be safe, effective, and reduced the need for splenectomy [<a href="#rid22">22,23,40,71</a>]. Use of these agents in the management of ITP is discussed in detail separately [<a href="#rid72">72,73</a>]. (See  <a class="medical medical_review" href="/d/html/6678.html" rel="external">"Second-line and subsequent therapies for immune thrombocytopenia (ITP) in adults", section on 'TPO receptor agonists'</a>.)</p><p class="headingAnchor" id="H22"><span class="h2">Liver disease</span></p><p class="headingAnchor" id="H558386947"><span class="h3">Rationale</span><span class="headingEndMark"> — </span>The thrombocytopenia seen in liver disease can be due to several mechanisms. These include an immune thrombocytopenia (ITP)-like process that is commonly seen in patients with chronic hepatitis C virus (HCV) infection and usually responds to the standard ITP treatments. Another mechanism is splenic pooling of platelets when portal hypertension causes splenic enlargement. Finally, thrombocytopenia can result from reduced TPO production by a damaged liver. Studies of liver transplantation have shown that TPO levels are often undetectable pre-transplantation and rise immediately post-transplantation, followed by a rise in peripheral platelet count but no change in spleen size [<a href="#rid74">74,75</a>].</p><p class="headingAnchor" id="H23"><span class="h3">Chronic HCV infection</span><span class="headingEndMark"> — </span>Hepatitis C treatments rarely use interferon-based therapy. However, when interferon was used, <a class="drug drug_general" data-topicid="9051" href="/d/drug information/9051.html" rel="external">eltrombopag</a> was shown to be effective in raising the platelet count in a series of 74 patients with chronic HCV and platelet counts in the range of 20,000/microL to 70,000/microL. Patients were treated for four weeks with placebo or eltrombopag at doses of 30, 50, or 75 mg/day daily in a blinded, randomized phase II study [<a href="#rid41">41</a>]. In a subsequent, large, phase III study, all patients with HCV infection and platelet count under 100,000/microL were treated with eltrombopag before initiation of antiviral treatment, and 95 percent increased their platelet count to over 100,000/microL by week 9 [<a href="#rid76">76</a>]. Patients were then randomized to receive either eltrombopag or placebo during the next 24 to 48 weeks of antiviral treatment. More patients on eltrombopag maintained a platelet count &gt;50,000/microL than those receiving placebo (69 to 81 percent versus 15 to 23 percent, respectively), and there was a higher rate of sustained virologic response in those on eltrombopag than in those on placebo (19 to 23 percent versus 13 to 15 percent). Based on these data, eltrombopag was approved for the treatment of thrombocytopenia in patients with chronic HCV to allow the initiation and maintenance of interferon-based therapy.</p><p class="headingAnchor" id="H558387015"><span class="h3">Advanced liver disease</span><span class="headingEndMark"> — </span>In a randomized trial, administration of <a class="drug drug_general" data-topicid="9051" href="/d/drug information/9051.html" rel="external">eltrombopag</a> to patients with advanced chronic liver disease and cirrhosis raised platelet counts and reduced the need for platelet transfusions prior to invasive procedures [<a href="#rid77">77</a>]. However, this was associated with an apparent increase in portal vein thrombosis, resulting in premature termination of the trial. Given the high rate of asymptomatic portal vein thrombosis in this patient population, the failure to determine the pretreatment rate of thrombosis is a major limitation of this trial. However, a similar trial with <a class="drug drug_general" data-topicid="117929" href="/d/drug information/117929.html" rel="external">avatrombopag</a> did not find an increased rate of thrombosis. When compared with placebo, avatrombopag for five days raised the platelet count, reduced platelet transfusions, and was not associated with any increase in thrombosis; all patients underwent ultrasound evaluation of the portal vein [<a href="#rid8">8</a>]. Although most patients underwent low-risk procedures (endoscopy, liver biopsy), World Health Organization (WHO) bleeding &gt;grade 2 occurred in under 5 percent of participants and was not related to treatment. Identical beneficial outcomes were seen with short-term administration of <a class="drug drug_general" data-topicid="118602" href="/d/drug information/118602.html" rel="external">lusutrombopag</a>. The use of these agents in patients with liver disease is discussed separately. (See  <a class="medical medical_review" href="/d/html/13932.html" rel="external">"Hemostatic abnormalities in patients with liver disease"</a>.)</p><p class="headingAnchor" id="H4239418666"><span class="h2">Aplastic anemia</span><span class="headingEndMark"> — </span>The use of a TPO receptor agonist might be predicted to have little benefit in patients with aplastic anemia (AA), given that TPO levels are usually elevated 10- to 20-fold greater than normal values of 25 to 100 pg/mL [<a href="#rid78">78</a>]. However, both <a class="drug drug_general" data-topicid="9051" href="/d/drug information/9051.html" rel="external">eltrombopag</a> and <a class="drug drug_general" data-topicid="9493" href="/d/drug information/9493.html" rel="external">romiplostim</a> have been shown to be effective in improving hematologic parameters in AA, including neutropenia, anemia, and thrombocytopenia in adults who are unable to undergo hematopoietic cell transplantation [<a href="#rid43">43</a>]. Some patients attaining near normal blood counts were able to discontinue treatment [<a href="#rid42">42</a>]. </p><p>This unexpected result has led to an improved understanding of the mechanism of TPO in aplastic anemia. It appears that interferon gamma (levels of which are highly elevated in aplastic anemia) directly binds to endogenous TPO and prevents its interaction with the TPO receptor on hematopoietic precursor cells. This block in TPO-mediated hematopoiesis leads to pancytopenia and the elevated TPO levels. Since <a class="drug drug_general" data-topicid="9051" href="/d/drug information/9051.html" rel="external">eltrombopag</a> and presumably <a class="drug drug_general" data-topicid="9493" href="/d/drug information/9493.html" rel="external">romiplostim</a> are not "neutralized" by interferon gamma, they can still activate the TPO receptor and restore hematopoiesis [<a href="#rid79">79</a>]. (See  <a class="medical medical_review" href="/d/html/7152.html" rel="external">"Aplastic anemia: Pathogenesis, clinical manifestations, and diagnosis"</a>.)</p><p>A 2017 study has shown that the addition of <a class="drug drug_general" data-topicid="9051" href="/d/drug information/9051.html" rel="external">eltrombopag</a> to standard immunosuppression therapy from day 1 to month 6 of treatment resulted in a complete hematologic remission in 58 percent and overall response of 94 percent, compared with historical rates of 10 and 66 percent, respectively [<a href="#rid80">80</a>]. A 2019 study found that <a class="drug drug_general" data-topicid="9493" href="/d/drug information/9493.html" rel="external">romiplostim</a> at 10 mcg/kg weekly produced a platelet response in 70 percent of individuals treated [<a href="#rid30">30</a>]. Some had multilineage responses; responses were durable. Management of aplastic anemia is discussed separately. (See  <a class="medical medical_review" href="/d/html/7158.html" rel="external">"Treatment of aplastic anemia in adults"</a>.)</p><p class="headingAnchor" id="H9580690"><span class="h1">OTHER POTENTIAL USES OF TPO RECEPTOR AGONISTS</span></p><p class="headingAnchor" id="H923761950"><span class="h2">Myelodysplastic syndromes</span><span class="headingEndMark"> — </span>Bone marrow from some patients with myelodysplastic syndrome (MDS) can be stimulated in vitro to form megakaryocytes, suggesting that some patients might benefit from administration of TPO [<a href="#rid81">81</a>]. In one early study of 21 patients, treatment with PEG-rHuMGDF doubled the platelet count after five weeks of treatment [<a href="#rid82">82</a>]. One individual with MDS was treated for over 450 days; while the platelet count rose from &lt;10,000/microL to 50,000/microL, there were also effects on other cell lines, with the hemoglobin rising to &gt;13 g/dL [<a href="#rid59">59</a>].</p><p>In general, <a class="drug drug_general" data-topicid="9493" href="/d/drug information/9493.html" rel="external">romiplostim</a> treatment increased the platelet count and reduced the need for platelet transfusions in patients with MDS receiving chemotherapy or supportive care [<a href="#rid24">24-26</a>]. One trial randomly assigned thrombocytopenic patients with low/intermediate-1-risk MDS (platelet count &lt;20,000/microL or history of bleeding along with platelets &lt;50,000/microL) to receive romiplostim or placebo for 58 weeks [<a href="#rid83">83</a>]. The primary study endpoints, clinically important bleeding events, were not significantly reduced with romiplostim (hazard ratio [HR], 0.83; 95% CI 0.66-1.05), but in those with platelet counts &gt;20,000/microL, significant reductions were seen (HR, 0.34; 95% CI 0.20-0.58). Romiplostim reduced all bleeding events (relative risk [RR], 0.92) and platelet transfusions (RR, 0.77) and increased platelet response (odds ratio [OR], 15.6). This study was stopped at an interim analysis because of a perceived increase in AML rate (HR, 2.51) with romiplostim, but the final analysis showed AML rates of 6 percent with romiplostim and 4.9 percent placebo (HR, 1.20; 95% CI 0.38-3.84) and similar survival rates. The management of MDS is discussed separately. (See  <a class="medical medical_review" href="/d/html/16122.html" rel="external">"Overview of the treatment of myelodysplastic syndromes"</a>.) </p><p>Because of the concern that TPO receptor agonists might promote leukemic transformation, the benefit of <a class="drug drug_general" data-topicid="9051" href="/d/drug information/9051.html" rel="external">eltrombopag</a> has been carefully assessed. Paradoxically, eltrombopag was found to inhibit leukemic cell growth in tissue culture and in animal models of leukemia [<a href="#rid84">84</a>]. When studied in 98 thrombocytopenic patients with advanced MDS or AML who were not receiving chemotherapy, there was no effect on peripheral blood or bone marrow blast counts and no effect upon overall progression-free survival or overall survival [<a href="#rid85">85</a>]. However, there was also no significant effect on platelet counts (eltrombopag: 17,000/microL; placebo: 12,000/microL), grade 3 bleeds (eltrombopag: 16 percent; placebo: 26 percent), or RBC or platelet transfusions.</p><p>Guidelines for MDS from the National Comprehensive Cancer Network (NCCN) suggest consideration of TPO receptor agonists in low-risk MDS patients with severe or life-threatening thrombocytopenia [<a href="#rid86">86</a>]. (See  <a class="medical medical_review" href="/d/html/15776.html" rel="external">"Myelodysplastic syndromes/neoplasms (MDS): Management of hematologic complications in lower-risk MDS", section on 'Refractory bleeding'</a>.)</p><p class="headingAnchor" id="H3506077319"><span class="h2">MYH9-related congenital thrombocytopenia</span><span class="headingEndMark"> — </span>Of the congenital thrombocytopenias, non-muscle heavy-chain myosin-9 (MYH9)-related thrombocytopenias are associated with a number of distinct clinical syndromes and MYH9 mutations [<a href="#rid87">87</a>]. Most have mild thrombocytopenia with minimal bleeding; however, some have more severe thrombocytopenia with associated increased bleeding risk. In one study, 12 adults with MYH9-related thrombocytopenia (platelets &lt;50,000/microL) were treated with <a class="drug drug_general" data-topicid="9051" href="/d/drug information/9051.html" rel="external">eltrombopag</a> 50 mg daily for at least three weeks [<a href="#rid88">88</a>]. In eight patients the platelet count either rose above 100,000/microL or three times baseline; three patients doubled their baseline platelet count; only one patient failed to respond. Bleeding decreased in 8 of 10 individuals who had bleeding at baseline. Only two patients had mild adverse events. (See  <a class="medical medical_review" href="/d/html/6675.html" rel="external">"Inherited platelet function disorders (IPFDs)", section on 'MYH9-related disease'</a>.)</p><p class="headingAnchor" id="H3848189693"><span class="h2">HIV-associated thrombocytopenia</span><span class="headingEndMark"> — </span>In a single study of six HIV-infected patients with thrombocytopenia treated with PEG-rHuMGDF, all six normalized platelet counts [<a href="#rid89">89</a>]. The reported mechanism of effect was a reduction in the rate of megakaryocyte apoptosis (and hence increased rate of platelet production) due to the PEG-rHuMGDF. Although there is only a small number of case reports demonstrating the efficacy of TPO receptor agonists in HIV-associated thrombocytopenia [<a href="#rid90">90,91</a>], this author has found major platelet count increases in multiple HIV-infected patients with platelet counts &lt;10,000/microL after treatment with TPO receptor agonists; many of these patients were assumed to have "secondary ITP" due to HIV. The management of HIV-associated thrombocytopenia is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/6679.html" rel="external">"HIV-associated cytopenias", section on 'Thrombocytopenia'</a>.) </p><p class="headingAnchor" id="H9580743"><span class="h2">Chemotherapy</span><span class="headingEndMark"> — </span>Chemotherapy patients use approximately 25 percent of all platelet products transfused in the United States. Chemotherapy drugs such as <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a> and <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> cause significant thrombocytopenia (platelets &lt;25,000/microL) in up to 7 percent of patients [<a href="#rid92">92</a>]. This is a major area in which thrombopoietic growth factors might show benefit in the primary or secondary prophylaxis of thrombocytopenia [<a href="#rid92">92</a>]. In several animal models of radiation- and chemotherapy-induced thrombocytopenia, administration of recombinant thrombopoietins was associated with a slightly earlier platelet nadir, shorter duration of thrombocytopenia, and, in other animal models, a reduction in the depth of the platelet nadir (<a class="graphic graphic_figure graphicRef82447" href="/d/graphic/82447.html" rel="external">figure 6</a>) [<a href="#rid93">93</a>]. The duration of neutropenia and anemia was also shortened in some animal studies.</p><p>Before considering TPO receptor agonists for the treatment of chemotherapy-induced thrombocytopenia, it is important to note that the TPO receptor (c-mpl) is either not present or is inactive in solid tumor cells [<a href="#rid94">94,95</a>]. It is also important to note that the thrombocytopenia in <strong>non-myeloablative chemotherapy</strong> is distinct from that of <strong>myeloablative chemotherapy</strong> or <strong>hematopoietic cell transplantation</strong> (HCT) in that the latter are associated with very high levels of endogenous TPO that may not benefit from the addition of further recombinant TPO or <a class="drug drug_general" data-topicid="9493" href="/d/drug information/9493.html" rel="external">romiplostim</a>. Indeed, older studies (1995 through 1998) with the recombinant thrombopoietins showed improved platelet counts in the non-myeloablative chemotherapy regimens but little or no effect in the myeloablative regimes or HCT. (See <a class="local">'Hematopoietic cell transplantation'</a> below.) </p><p>However, given the unique mechanism of action of <a class="drug drug_general" data-topicid="9051" href="/d/drug information/9051.html" rel="external">eltrombopag</a>, <a class="drug drug_general" data-topicid="117929" href="/d/drug information/117929.html" rel="external">avatrombopag</a>, and <a class="drug drug_general" data-topicid="118602" href="/d/drug information/118602.html" rel="external">lusutrombopag</a> and their ability to potentiate the effect of endogenous TPO, there is some enthusiasm for studies with these agents in the myeloablative/HCT settings.</p><p class="headingAnchor" id="H9580750"><span class="h3">Solid tumors</span><span class="headingEndMark"> — </span>Following the administration of recombinant TPO to humans undergoing non-myeloablative chemotherapy, platelet recovery was enhanced but, unlike the animal models, with no change in the recovery of white or red blood cells.</p><p class="bulletIndent1"><span class="glyph">●</span>One study, for example, evaluated 53 patients with lung cancer treated with <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a> and <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> [<a href="#rid96">96</a>]. Thirty-eight received doses of PEG-rHuMGDF ranging from 0.03 to 5 mcg/kg daily after chemotherapy and 15 received placebo. Patients who received PEG-rHuMGDF had a significantly higher platelet nadir than those treated with placebo (188,000/microL versus 111,000/microL) and an earlier return of their platelet counts to baseline (14 versus 21 days) (<a class="graphic graphic_figure graphicRef74521" href="/d/graphic/74521.html" rel="external">figure 7</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a second trial, 41 cancer patients treated with <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a> and <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> were randomly assigned to receive either PEG-rHuMGDF or placebo [<a href="#rid97">97</a>]. There was no effect on the platelet nadir although the patients who received PEG-rHuMGDF had an earlier return of their platelet counts to baseline (17 versus 22 days).</p><p></p><p>Although these studies demonstrated that recombinant TPO has activity in the chemotherapy setting and is safe, as no adverse events were attributed to the PEG-rHuMGDF, they were not designed to show a reduction in the need for platelet transfusions. Few of the patients received platelet transfusions because the dose intensity of the chemotherapy was not high enough. However, in a third trial using a dose-intense chemotherapy regimen to treat patients with ovarian cancer, rHuTPO elevated nadir platelet counts, reduced the duration of thrombocytopenia, along with an over 50 percent reduction in the need for platelet transfusions (<a class="graphic graphic_figure graphicRef77335" href="/d/graphic/77335.html" rel="external">figure 8</a>) [<a href="#rid98">98</a>].</p><p>It is not clear if eliminating treatment delays by using thrombopoietic agents and thereby maintaining the dose intensity of ICE chemotherapy would translate into better clinical outcomes. A randomized, double-blind, placebo-controlled phase I/II trial of PEG-rHuMGDF in combination with <a class="drug drug_general" data-topicid="8446" href="/d/drug information/8446.html" rel="external">filgrastim</a> studied 38 patients with relapsed, refractory aggressive NHL who were given ICE chemotherapy for stem cell mobilization prior to autologous HCT with the following results [<a href="#rid99">99</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients given PEG-rHuMGDF had significantly less grade IV thrombocytopenia (35 versus 15 percent) and a significantly higher median nadir platelet count (49,000/microL versus 20,000/microL) compared with those given placebo.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients given PEG-rHuMGDF were more likely to receive ICE on schedule (77 versus 44 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients who went on to receive HCT, overall survival was significantly higher in those who received their therapy on schedule compared with those whose therapy was delayed (73 versus 13 percent).</p><p></p><p>Recombinant TPO is extensively used to support chemotherapy in China [<a href="#rid9">9</a>]. However, the TPO receptor agonists have not been extensively studied in chemotherapy-associated thrombocytopenia. The following summarizes the major studies:</p><p class="bulletIndent1"><span class="glyph">●</span>A 2017 Cochrane review identified two trials comparing a TPO receptor agonist with placebo in individuals with solid tumors who were receiving chemotherapy and concluded evidence was insufficient to determine whether these drugs reduced bleeding or the need for platelet transfusions [<a href="#rid100">100</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>One of the trials randomly assigned 26 patients receiving <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> chemotherapy regimens to receive <a class="drug drug_general" data-topicid="9051" href="/d/drug information/9051.html" rel="external">eltrombopag</a> or placebo prophylaxis starting at cycle 2 and found higher nadir platelet counts in the eltrombopag group (115,000/microL versus 53,000/microL, respectively) [<a href="#rid101">101</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Another trial assigned 183 patients receiving <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a>/<a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> regimens for solid tumors to <a class="drug drug_general" data-topicid="9051" href="/d/drug information/9051.html" rel="external">eltrombopag</a> (a series of doses) or placebo and found higher post-nadir platelet counts in the eltrombopag groups [<a href="#rid102">102</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another Phase II study assigned patients with solid tumors receiving <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> monotherapy or gemcitabine plus <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a>/<a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a> to either <a class="drug drug_general" data-topicid="9051" href="/d/drug information/9051.html" rel="external">eltrombopag</a> 100 mg (n = 52) or placebo (n = 23) for five days before and after chemotherapy was started [<a href="#rid44">44</a>]. The primary endpoint (prechemotherapy [day 1] platelet count across chemotherapy cycles) was higher with eltrombopag. Platelet transfusions were fewer and platelet counts were higher in those on eltrombopag, but none reached statistical significance.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a case series of 20 patients treated with <a class="drug drug_general" data-topicid="9493" href="/d/drug information/9493.html" rel="external">romiplostim</a> for prolonged chemotherapy-induced thrombocytopenia, 19 demonstrated improvement in platelet counts; chemotherapy could be resumed at full doses in 15 (75 percent) [<a href="#rid103">103</a>]. The mean dose to achieve adequate platelet counts was 2.9 mcg/kg weekly. There were no significant toxicities. Three deep vein thromboses occurred, which was considered similar to the anticipated rates of thrombosis in patients with cancer on active chemotherapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a small randomized trial of solid tumor patients with chemotherapy-associated thrombocytopenia, 14 of 15 romiplostim-treated patients (93 percent) experienced correction of their platelet count within three weeks, compared with one of eight control patients (12.5 percent; P &lt;0.001) [<a href="#rid28">28</a>]. The mean platelet count at two weeks of treatment was 141,000/microL versus 57,000/microL in the eight observation patients at 3 weeks.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a large retrospective multi-center study of <a class="drug drug_general" data-topicid="9493" href="/d/drug information/9493.html" rel="external">romiplostim</a> in 173 patients with chemotherapy-associated thrombocytopenia, 71 percent of patients had a platelet count response to over 100,000/microL, and the median platelet count on romiplostim was 116,000/microL versus 60,000/microL before treatment [<a href="#rid104">104</a>]. Chemotherapy dose reductions/delays were avoided in 79 percent, and 89 percent avoided platelet transfusions.</p><p></p><p class="headingAnchor" id="H9580757"><span class="h3">Acute leukemia</span><span class="headingEndMark"> — </span>In contrast to non-myeloablative chemotherapy for solid tumors, the administration of PEG-rHuMGDF following chemotherapy for acute leukemia has failed to produce enhancement of platelet recovery when given after standard myeloablative induction regimens [<a href="#rid105">105,106</a>]. The reasons for this failure are not entirely clear. They may relate to the absence of sufficient bone marrow progenitor cells upon which to act, high endogenous TPO levels, or an inappropriate administration scheme [<a href="#rid107">107,108</a>]. Attempts to increase the dose of TPO or to alter the dosing scheme (eg, to include doses prior to, during, or after induction or consolidation chemotherapy) did not have an effect on the platelet count [<a href="#rid109">109</a>]. Indeed, neutropenia was actually prolonged when the TPO was given during chemotherapy. </p><p>The administration of <a class="drug drug_general" data-topicid="9051" href="/d/drug information/9051.html" rel="external">eltrombopag</a> during induction chemotherapy for acute myeloid leukemia was found not to be helpful [<a href="#rid110">110</a>]. Starting at day 4 of a standard <a class="drug drug_general" data-topicid="9326" href="/d/drug information/9326.html" rel="external">daunorubicin</a>/<a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">cytarabine</a> induction course, patients received 200 mg/day eltrombopag (n = 74) or placebo (n = 74) until remission or day 42. Eltrombopag patients had an increased death rate (53 percent versus 41 percent) than those on placebo.</p><p class="headingAnchor" id="H9580764"><span class="h2">Hematopoietic cell transplantation</span><span class="headingEndMark"> — </span>Although comprising a small number of patients, hematopoietic cell transplant (HCT) recipients, especially those who have delayed or absent engraftment of platelets, consume a disproportionately large amount of the national supply of platelets. Accordingly, stimulation of megakaryocyte and platelet engraftment after HCT is an important potential use of TPO.</p><p class="headingAnchor" id="H2756465499"><span class="h2">Stem cell mobilization</span><span class="headingEndMark"> — </span>In mice, TPO administration improved stem cell harvests and subsequent engraftment. When donor animals were treated with recombinant TPO and the TPO-stimulated marrow then transplanted into recipient animals, there was a reduction in the duration of thrombocytopenia as well as earlier recovery of erythrocytes (<a class="graphic graphic_figure graphicRef50458" href="/d/graphic/50458.html" rel="external">figure 9</a>) [<a href="#rid111">111</a>].</p><p>In oncology patients, administration of rHuTPO efficiently mobilizes peripheral blood progenitor cells. When combined with chemotherapy and <a class="drug drug_general" data-topicid="8446" href="/d/drug information/8446.html" rel="external">filgrastim</a> (G-CSF), PEG-rHuMGDF produced a 250-fold increase in the number of circulating megakaryocyte colony forming cells (Meg-CFC), a 190-fold increase in granulocyte- macrophage-CFC, a 65-fold increase in erythroid burst forming cells and a 24-fold increase in CD34+ cells when compared with patients receiving only chemotherapy and filgrastim (<a class="graphic graphic_figure graphicRef61207" href="/d/graphic/61207.html" rel="external">figure 10</a>) [<a href="#rid97">97</a>]. (See  <a class="medical medical_review" href="/d/html/3537.html" rel="external">"Hematopoietic cell transplantation (HCT): Sources of hematopoietic stem/progenitor cells"</a>.)</p><p>The utility of simultaneous G-CSF (5 mcg/kg SQ or IV twice daily on days three to eight) and rHuTPO (total dose 0.6 to 2.4 mcg/kg IV) for peripheral blood stem cell mobilization was studied in 29 breast cancer patients; a concurrent group of 20 patients receiving G-CSF only served as controls [<a href="#rid112">112</a>]. CD34+ cell yields in the first apheresis (day 6) were 4.1 and 0.8 x 10<sup>6</sup> cells/kg for the G-CSF/TPO and G-CSF groups, respectively. The targeted minimum yield of 3 x 10<sup>6</sup> CD34+ cells/kg was procured following a single apheresis in 61 and 10 percent of subjects in the G-CSF/TPO and G-CSF groups, respectively. Use of TPO with G-CSF modestly accelerated platelet and granulocyte recovery post-chemotherapy and modestly reduced RBC transfusion requirements; no adverse toxicities were noted [<a href="#rid112">112</a>].</p><p class="headingAnchor" id="H2224712222"><span class="h3">Stem cell engraftment</span><span class="headingEndMark"> — </span>The results of administration of PEG-rHuMGDF or rHuTPO after autologous HCT in general have been disappointing, with no significant enhancement of platelet recovery and no reduction in platelet transfusions. Several approaches have been tried:</p><p class="bulletIndent1"><span class="glyph">●</span>In one report, rHuTPO was administered to patients who had received either bone marrow or peripheral blood stem cell transplants in whom platelets had failed to engraft after 30 days [<a href="#rid113">113</a>]. Only 3 of 37 patients showed increased bone marrow megakaryocytes, and only two became transfusion-independent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A second study evaluated patients with breast cancer undergoing autologous HCT using bone marrow stem cells (STAMP V regimen) who were given PEG-rHuMGDF immediately after the stem cell infusion [<a href="#rid114">114</a>]. There was no effect on the number of days that the patients had severe thrombocytopenia (ie, a platelet count &lt;20,000/microL) or on the time to platelet recovery. However, there was a dose-dependent rebound in the post-transplant platelet count.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another series of patients with breast cancer treated with the STAMP I regimen, PEG-rHuMGDF was given before HCT (days minus 14 to minus 8) using peripheral blood stem cell infusion and, in some patients, after the infusion as well [<a href="#rid115">115</a>]. The PEG-rHuMGDF treatment increased the platelet count on the day of hematopoietic stem cell infusion (228,000 versus 107,000/microL) but had no effect on platelet recovery or the need for platelet transfusion.</p><p></p><p>The ultimate role of TPO in HCT may be to stimulate the number of progenitor cells in the marrow or peripheral stem cell population prior to harvesting. As suggested by murine models [<a href="#rid111">111</a>], it may be more important to use TPO to treat the stem cell <strong>donor</strong> rather than the recipient.</p><p class="headingAnchor" id="H246004253"><span class="h3">Delayed platelet engraftment</span><span class="headingEndMark"> — </span>Delayed engraftment of platelets is a major complication of HCT. In one retrospective series of 86 patients with persistent thrombocytopenia after allogeneic HCT (allo-HCT), administration of either <a class="drug drug_general" data-topicid="9493" href="/d/drug information/9493.html" rel="external">romiplostim</a> or <a class="drug drug_general" data-topicid="9051" href="/d/drug information/9051.html" rel="external">eltrombopag</a> starting a median of 127 days after allo-HCT was associated with platelet recovery in 72 percent of patients after a median of 66 days of treatment [<a href="#rid116">116</a>]. A systematic review of 25 reports of using TPO receptor agonists in patients with persistent thrombocytopenia after allo-HCT [<a href="#rid117">117</a>], demonstrated a durable platelet response in 70 percent of 121 patients receiving eltrombopag and 82 percent of 49 patients receiving romiplostim. Prospective studies in this area are indicated.</p><p>Additional discussions about management of thrombocytopenia following HCT are presented separately. (See  <a class="medical medical_review" href="/d/html/3538.html" rel="external">"Hematopoietic support after hematopoietic cell transplantation"</a> and  <a class="medical medical_review" href="/d/html/7918.html" rel="external">"Platelet transfusion: Indications, ordering, and associated risks", section on 'Leukemia, chemotherapy, and HSCT'</a>.)</p><p class="headingAnchor" id="H4128173144"><span class="h2">Surgery</span><span class="headingEndMark"> — </span>Cardiac surgery, liver transplantation, or other major surgery consume about 40 percent of all platelets transfused in North America, a need that might be ameliorated by administration of a TPO receptor agonist. Additionally, some patients may be unable to benefit from platelet transfusion due to alloimmunization or religious belief.</p><p>Evidence for the efficacy and safety of preoperative administration of TPO receptor agonists is limited to observational studies.</p><p class="bulletIndent1"><span class="glyph">●</span>In a series of 18 patients with thrombocytopenia of various etiologies who received <a class="drug drug_general" data-topicid="9493" href="/d/drug information/9493.html" rel="external">romiplostim</a> prior to elective surgical procedures (including three Jehovah's Witnesses), administration of romiplostim was effective in raising platelet counts in all cases (from a median of 47,000/microL to a median of 144,000/microL) [<a href="#rid118">118</a>]. There were no surgical delays or cancellations due to thrombocytopenia, and there were four postoperative bleeding episodes at platelet counts between 82,000/microL and 185,000/microL. There were no thromboembolic events directly related to the drug, although one patient had a urinary bladder catheter-associated clot after prostate surgery with a platelet count of 48,000/microL. An update of this study to include 51 surgical procedures in 47 thrombocytopenic individuals reported that median (range) baseline platelet counts rose from 47,000 (9000 to 120,000)/microL to 164,000 (28,000 to 603,000)/microL at the time of surgery [<a href="#rid29">29</a>]. A romiplostim dose of 3 mcg/kg per week for two doses increased the platelet count to &gt;100,000/microL in 79 percent of patients within 14 days.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a series of 35 patients with chronic hepatitis C who received <a class="drug drug_general" data-topicid="9493" href="/d/drug information/9493.html" rel="external">romiplostim</a> prior to elective surgical procedures, administration of romiplostim was effective in raising platelet counts in 33 (from a median of 31,000/microL to a maximum of 73,000/microL to 240,000/microL) [<a href="#rid119">119</a>]. There were no postoperative bleeding or thrombotic complications.</p><p></p><p>The optimal timing and dose of administration seems straightforward. In the studies above, <a class="drug drug_general" data-topicid="9493" href="/d/drug information/9493.html" rel="external">romiplostim</a> was administered for approximately two to four weeks prior to surgery, and dosing was in the range of 2 to 3 mcg/kg, administered once per week.</p><p>These reports suggest that <a class="drug drug_general" data-topicid="9493" href="/d/drug information/9493.html" rel="external">romiplostim</a> may be appropriate for some patients with a platelet count &lt;50,000/microL who are unable to receive platelet transfusions. While concerns regarding the possible exacerbation of thromboembolic disease remain, especially for patients with underlying thrombophilia and/or thrombosis, few were reported in the studies above. (See <a class="local">'Thrombocytosis and thrombosis'</a> below.)</p><p>A randomized trial of thrombocytopenic ITP patients requiring a procedure showed that <a class="drug drug_general" data-topicid="9051" href="/d/drug information/9051.html" rel="external">eltrombopag</a> was as efficient as <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">IVIG</a> in elevating the platelet count [<a href="#rid120">120</a>]. Perioperative platelet count targets were achieved for 29 of 37 patients (78 percent) in the eltrombopag group and 20 of 32 (63 percent) in the IVIG group.</p><p class="headingAnchor" id="H27"><span class="h2">Transfusion medicine</span><span class="headingEndMark"> — </span>In addition to its regulatory role in platelet production, TPO also has an important physiologic role in the regulation of early hematopoiesis [<a href="#rid121">121,122</a>]. As a result, there are potential applications for the use of TPO in stem cell expansion as well as stimulation of platelet production ex vivo and in vivo.</p><p class="headingAnchor" id="H28"><span class="h3">Ex vivo expansion of progenitor cells</span><span class="headingEndMark"> — </span>TPO in combination with other hematopoietic growth factors (eg, flt-3 ligand, IL-3) may be used to expand cord blood or peripheral blood progenitor cells ex vivo. In one study, for example, a simple cocktail of flt-3 ligand and TPO expanded cord blood progenitors several hundred-thousand-fold after 25 weeks in culture (<a class="graphic graphic_figure graphicRef57003" href="/d/graphic/57003.html" rel="external">figure 11</a>) [<a href="#rid123">123</a>]. These expanded progenitor populations appear to provide adequate hematopoietic reconstitution in mice [<a href="#rid124">124</a>].</p><p class="headingAnchor" id="H29"><span class="h3">Ex vivo platelet production</span><span class="headingEndMark"> — </span>Platelets can be produced in vitro under the stimulation of TPO. CD34+ and other precursor cells can be grown in the presence of TPO such that most of the cells become megakaryocytes and, in turn, shed platelets [<a href="#rid125">125</a>]. These shed platelets have normal ultrastructure and function compared with their in vivo counterparts [<a href="#rid126">126,127</a>]. Although probably not an economical source of platelets, a number of "platelet bioreactors" have been developed that can produce normal human platelets [<a href="#rid127">127-132</a>].</p><p class="headingAnchor" id="H30"><span class="h3">Increasing platelet apheresis yields</span><span class="headingEndMark"> — </span>rHuTPO and PEG-rHuMGDF stimulated platelet production in healthy apheresis donors and increased the apheresis yield (<a class="graphic graphic_figure graphicRef66293" href="/d/graphic/66293.html" rel="external">figure 12</a>) [<a href="#rid133">133,134</a>]. In another study, rHuTPO was given to cancer patients prior to chemotherapy and platelets were then harvested and frozen. Subsequent administration of these platelet products to their donors successfully ameliorated the thrombocytopenia associated with their chemotherapy [<a href="#rid135">135</a>]. Although this modality is no longer in development with recombinant thrombopoietins due to concerns regarding development of thrombocytopenia due to anti-TPO antibodies, similar treatment of healthy donors with current TPO receptor agonists could be considered. (See <a class="local">'Antibody formation'</a> below.)</p><p class="headingAnchor" id="H1535577"><span class="h2">Thrombocytopenia with absent radius syndrome</span><span class="headingEndMark"> — </span>The low platelet count in patients with the thrombocytopenia with absent radius (TAR) syndrome appears to result from failure of cell signaling events downstream from the TPO receptor [<a href="#rid136">136</a>]; the TPO receptor itself is not mutated. It is thus unlikely that exogenous TPO will be useful in this disorder; in vitro bone marrow studies did not show a response to recombinant TPO [<a href="#rid136">136</a>]. </p><p class="headingAnchor" id="H1535583"><span class="h2">Congenital amegakaryocytic thrombocytopenia</span><span class="headingEndMark"> — </span>Individuals with congenital amegakaryocytic thrombocytopenia (CAMT) have mutations in the TPO receptor that render them unable to respond to TPO [<a href="#rid137">137-139</a>]. They present with thrombocytopenia at birth and subsequently develop pancytopenia. In vitro, a few respond to recombinant TPO but most do not. However, a monoclonal antibody ("minibody") has been developed that binds the TPO receptor in a way different from TPO and has been shown in vitro to activate the mutated receptor [<a href="#rid140">140</a>]. However, no clinical studies have been conducted to confirm this finding and this antibody is no longer in clinical development.</p><p class="headingAnchor" id="H3740428145"><span class="h2">Radiation injury</span><span class="headingEndMark"> — </span>Severe thrombocytopenia may occur after therapeutic or accidental radiation exposure. TPO may have a bone marrow protective effect. When mice were given a high dose (950 rad) of total body irradiation (TBI), 83 percent of the mice died; but if they were given recombinant murine TPO (rMuTPO) two hours before the irradiation, only 25 percent died [<a href="#rid141">141-143</a>]. The protective effect on platelets was maximal from minus 2 to plus 4 hours after TBI but was still present if administered 24 hours after TBI. </p><p>Given the anti-apoptotic effect of TPO on hematopoietic stem cells [<a href="#rid144">144,145</a>], these studies suggest that there may be a narrow window in time during which administration of TPO may reverse the apoptotic effects of irradiation on stem cells. After sub-lethal TBI (5Gy) to rhesus monkeys, administration of TPO 24 hours later and continued for 21 days markedly reduced the subsequent thrombocytopenia and increased the reticulocyte count; even a single dose at 24 hours was almost as effective, and a reticulocyte response but not neutrophil response was also augmented [<a href="#rid146">146,147</a>]. The addition of GM-CSF or G-CSF daily for 14 days to the single dose of TPO at 24 hours markedly promoted a trilineage recovery [<a href="#rid148">148</a>]. </p><p>Despite these animal findings, the role for TPO in the treatment of radiation exposure in humans has not been well assessed for the TPO receptor agonists. In the only relevant study, <a class="drug drug_general" data-topicid="9051" href="/d/drug information/9051.html" rel="external">eltrombopag</a> was given to stem cell transplant patients conditioned with TBI [<a href="#rid149">149</a>]. The drug was safe, but there were insufficient patients to document a treatment benefit. </p><p><a class="drug drug_general" data-topicid="9493" href="/d/drug information/9493.html" rel="external">Romiplostim</a> was approved in 2021 by the FDA for acute radiation syndrome, based on animal studies [<a href="#rid150">150</a>]. Treatment of radiation injury is discussed separately. (See  <a class="medical medical_review" href="/d/html/6588.html" rel="external">"Management of radiation injury"</a>.)</p><p class="headingAnchor" id="H31"><span class="h1">IMPACT ON PLATELET TRANSFUSION</span><span class="headingEndMark"> — </span>There was much early enthusiasm for using thrombopoietin (TPO) in the acute treatment of thrombocytopenia in lieu of platelet transfusions [<a href="#rid151">151</a>]. However, since none of the thrombopoietic molecules hastens platelet formation from megakaryocytes and all take five days to start to increase platelet production [<a href="#rid15">15</a>], they will not replace platelet transfusions in the acute setting. Nevertheless, there remains interest in developing another substance (eg, SDF-1) that might stimulate platelet shedding from existing megakaryocytes and possibly reduce the need for acute platelet transfusions.</p><p>Except for nonmyeloablative chemotherapy, it is unlikely that TPO receptor agonists will have a major impact on the need for platelet transfusions. </p><p class="headingAnchor" id="H32"><span class="h1">SIDE EFFECTS AND RISKS</span><span class="headingEndMark"> — </span>For any hematopoietic growth factor, potential adverse effects must be carefully assessed. For the thrombopoietic growth factors a number of actual or potential toxicities have been identified (<a class="graphic graphic_table graphicRef74625" href="/d/graphic/74625.html" rel="external">table 3</a>). Cost may also be limiting in some settings.</p><p class="headingAnchor" id="H33"><span class="h2">Antibody formation</span><span class="headingEndMark"> — </span>Formation of antibodies to recombinant human hematopoietic growth factors (eg, granulocyte colony-stimulating factor, erythropoietin) has been relatively uncommon, but was a significant problem in the clinical development of the recombinant thrombopoietins.</p><p>In one report, approximately 8 percent of healthy volunteers developed thrombocytopenia after receiving three monthly injections of PEG-rHuMGDF. This was apparently due to the development of antibodies that cross-reacted with endogenous thrombopoietin, neutralized its biologic activity, and produced thrombocytopenia [<a href="#rid12">12</a>]. Platelet counts as low as 4000/microL were reported [<a href="#rid12">12,13</a>]. All patients eventually recovered once the antibody abated, but clinical development of PEG-rHuMGDF by Amgen was stopped in 1998 because of this side effect [<a href="#rid2">2</a>]. In comparison, administration of rHuTPO was not associated with neutralizing antibodies; post-marketing data in China have identified no neutralizing antibodies in over 700 patients treated with rHuTPO.</p><p>The TPO receptor agonists have been developed to minimize the formation of autoantibodies. The TPO non-peptide mimetics do not carry the risk of antibody formation. The antigenicity of the one peptide mimetic, <a class="drug drug_general" data-topicid="9493" href="/d/drug information/9493.html" rel="external">romiplostim</a>, has been extensively studied. Of 961 patients in 13 clinical trials, 60 patients developed antibodies against romiplostim (most against the carrier Fc portion) [<a href="#rid152">152</a>]; four neutralized romiplostim but were not associated with loss of platelet response. None cross-reacted with endogenous TPO.</p><p class="headingAnchor" id="H34"><span class="h2">Thrombocytosis and thrombosis</span></p><p class="headingAnchor" id="H558386901"><span class="h3">Portal vein thrombosis</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9051" href="/d/drug information/9051.html" rel="external">Eltrombopag</a> may be associated with a risk of thrombosis in the portal venous system in patients with advanced liver disease. One randomized trial (292 patients) of eltrombopag versus placebo in patients with chronic liver disease or cirrhosis from all causes undergoing elective invasive procedures showed an increase in thrombotic events (seven in the eltrombopag group versus three in the placebo group; odds ratio [OR]: 3.04, 95% CI 0.62-14.82) [<a href="#rid77">77</a>]. Five of six patients with thrombosis had platelet counts over 200,000/microL. It is unclear whether these asymptomatic portal vein thromboses were due to the eltrombopag or the underlying liver disease, as imaging studies were not performed pretreatment to assess for thromboses that might have been present before eltrombopag treatment. In a much larger group of hepatitis patients, interferon and <a class="drug drug_general" data-topicid="9860" href="/d/drug information/9860.html" rel="external">ribavirin</a> treatment was supported with either eltrombopag (in 955 patients) or placebo (in 484 patients) and all patients underwent screening for thrombosis [<a href="#rid76">76</a>]. Eltrombopag treatment was associated with an increased rate of thromboembolic events (5.8 per 100 patient-years versus 1.9 per 100 patient-years) and slightly increased rate of portal vein thrombosis (1.25 versus 0.4 percent). Since eltrombopag treatment allowed higher dosing of antivirals, it is unclear whether the eltrombopag or the interferon plus ribavirin was the causative factor [<a href="#rid41">41</a>].</p><p>An increased rate of portal vein thrombosis has not been seen in trials of <a class="drug drug_general" data-topicid="117929" href="/d/drug information/117929.html" rel="external">avatrombopag</a> or <a class="drug drug_general" data-topicid="118602" href="/d/drug information/118602.html" rel="external">lusutrombopag</a> in liver disease patients being prepared for invasive procedures. This may reflect an underlying difference with <a class="drug drug_general" data-topicid="9051" href="/d/drug information/9051.html" rel="external">eltrombopag</a> or, more likely, the short exposure and relatively low platelet count elevations targeted by these two therapies. (See  <a class="medical medical_review" href="/d/html/13932.html" rel="external">"Hemostatic abnormalities in patients with liver disease", section on 'Invasive procedures'</a>.)</p><p class="headingAnchor" id="H1535664"><span class="h3">Lack of increased thrombosis in ITP</span><span class="headingEndMark"> — </span>ITP is associated with an increased baseline risk of venous and arterial thrombosis and this risk rises as the platelet count falls [<a href="#rid153">153,154</a>]. In randomized trials and other studies, the use of TPO receptor agonists did not increase the rate of thrombosis compared with placebo [<a href="#rid21">21,23,38,40,155</a>]. In those studies, thromboses occurred at both low and high platelet counts.</p><p class="headingAnchor" id="H558386935"><span class="h3">Potential mechanisms of thrombosis</span><span class="headingEndMark"> — </span>There are several potential prothrombotic mechanisms of the TPO receptor agonists that deserve attention:</p><p class="bulletIndent1"><span class="glyph">●</span>These molecules can be extremely potent thrombopoietic growth factors and can markedly elevate the platelet count in a short period of time. In a baboon model, the deposition of platelets in an extravascular shunt, which mimics an ulcerated atheroma in humans, was directly related to the platelet count after PEG-rHuMGDF administration [<a href="#rid16">16,156</a>]. Except for its ability to elevate the platelet count, PEG-rHuMGDF did not synergize with or exacerbate platelet deposition. Nevertheless, increasing the platelet count in individuals with active arterial thrombotic disease may increase the risk of thrombosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Platelets produced by stimulation with any of the recombinant thrombopoietins have normal aggregation responses. However, when the recombinant thrombopoietins (but not the non-peptide TPO receptor agonists) are added directly to platelets (or persist at elevated levels in the circulation in vivo), they decrease by approximately 50 percent the threshold for activation by various platelet agonists (eg, ADP, collagen) in platelet aggregometry studies [<a href="#rid16">16,156</a>]. This is probably not clinically relevant, since studies with recombinant thrombopoietins in oncology patients, a patient group with an inherent increased rate of thrombosis, showed no increased rate of thrombosis. Furthermore, treatment of baboons with PEG-rHuMGDF did not increase fibrin deposition in extravascular shunts despite marked increases in platelet count [<a href="#rid16">16,156</a>]. Finally, in the rabbit carotid artery model, PEG-rHuMGDF did not alter "cyclic flow reduction", a sensitive test of platelet-dependent thrombosis [<a href="#rid157">157</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>TPO receptor agonists may increase the rate of microparticle formation in patients with ITP [<a href="#rid158">158</a>]. Microparticles in turn increase the rate of thrombin generation and are associated with increased rates of thrombosis in many disorders of increased platelet turnover.</p><p></p><p class="headingAnchor" id="H35"><span class="h2">Bone marrow fibrosis</span><span class="headingEndMark"> — </span>In several preclinical models, murine bone marrow was transfected with the thrombopoietin gene, causing thrombopoietin to be expressed at very high levels in the bone marrow of mice following transplantation. Most of these mice developed extensive marrow fibrosis similar to that seen in primary myelofibrosis [<a href="#rid159">159-161</a>]. This fibrotic response is probably secondary to the high local bone marrow concentrations of transforming growth factor beta1 (TGF-beta1) and other factors [<a href="#rid162">162</a>].</p><p>Administration of recombinant thrombopoietin to mice produces increased bone marrow reticulin, which is reversible upon discontinuation of treatment [<a href="#rid163">163</a>]. There has been little clinical evidence for bone marrow fibrosis in humans given rHuTPO or PEG-rHuMGDF. However, one case series using serial analyses of bone marrow and peripheral blood in nine patients who received rHuTPO after induction therapy for acute myeloid leukemia (AML) and in eight patients undergoing the same AML induction treatment but without rHuTPO treatment showed increased bone marrow cellularity in eight of the nine rHuTPO-treated and five of the eight control patients [<a href="#rid164">164</a>]. Eight of nine rHuTPO-treated and two of six control patients had increased bone marrow reticulin staining. These morphologic findings resolved within 42 days of the last dose of rHuTPO. Given the brevity of most exposures and the lack of routine bone marrow analysis, this potential issue was not fully explored.</p><p><a class="drug drug_general" data-topicid="9493" href="/d/drug information/9493.html" rel="external">Romiplostim</a> causes a reversible increase in reticulin in rats [<a href="#rid165">165</a>]. Thus far, fewer than 5 percent of ITP subjects treated with the TPO receptor agonists have been reported to have increased reticulin. In some it was present at baseline; in others it increased from pretreatment levels, and receded upon discontinuation of treatment; in others it increased and then decreased despite continued therapy. Only a rare patient exhibited signs of collagen formation in addition to reticulin [<a href="#rid166">166</a>]. No patient developed other cytopenias or a myeloproliferative syndrome [<a href="#rid167">167</a>]. A three-year prospective bone marrow study with romiplostim in patients with ITP showed that 9 of 131 patients (7 percent) had increases in reticulin of ≥2 grades, and two of the nine also had increased collagen [<a href="#rid167">167</a>]. It was unclear if the frequency of reticulin increased with exposure time: increased reticulin occurred in 3 of 41 after one year, 1 of 38 after two years, and 5 of 52 after three years. Three of the nine patients had repeat biopsies after stopping romiplostim and all had disappearance of the reticulin and collagen.</p><p>A similar prospective bone marrow study has been done in ITP patients treated with <a class="drug drug_general" data-topicid="9051" href="/d/drug information/9051.html" rel="external">eltrombopag</a> [<a href="#rid166">166,168</a>]. In 93 patients who had bone marrow examinations at baseline and then after one and two years of treatment, 89 percent had no reticulin (MF-0) and 11 percent had mild reticulin (MF-1). Only one patient showed collagen deposition. These studies indicate that bone marrow biopsies need not be done on patients treated with TPO receptor agonists, unless other peripheral blood findings suggest otherwise. </p><p class="headingAnchor" id="H1637684806"><span class="h2">Hepatotoxicity</span><span class="headingEndMark"> — </span>The risk of hepatic decompensation is included in a Boxed Warning in the product information for <a class="drug drug_general" data-topicid="9051" href="/d/drug information/9051.html" rel="external">eltrombopag</a> when used in combination with interferon or <a class="drug drug_general" data-topicid="9860" href="/d/drug information/9860.html" rel="external">ribavirin</a> in individuals with chronic hepatitis C virus infection [<a href="#rid169">169</a>]. In this patient group, eltrombopag administration was associated with hyperbilirubinemia in 54 percent, compared with 25 percent in those who received placebo, and hepatic decompensation in 10 percent, compared with 5 percent in those who received placebo [<a href="#rid76">76</a>]. In ITP patients, liver function abnormalities occurred in about 11 percent; in general, these effects were mild and resolved with drug discontinuation (with many resuming the drug with no recurrence) [<a href="#rid38">38</a>].</p><p>The serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), and bilirubin should be measured prior to initiation of <a class="drug drug_general" data-topicid="9051" href="/d/drug information/9051.html" rel="external">eltrombopag</a>, every two weeks during dose titration, and monthly during stable dosing. Eltrombopag should be discontinued if there are progressive or persistent increases or other clinical signs of liver injury or hepatic decompensation.</p><p>Hepatotoxicity has not been reported with <a class="drug drug_general" data-topicid="9493" href="/d/drug information/9493.html" rel="external">romiplostim</a> or <a class="drug drug_general" data-topicid="117929" href="/d/drug information/117929.html" rel="external">avatrombopag</a> [<a href="#rid45">45</a>].</p><p class="headingAnchor" id="H1731264"><span class="h2">Rebound thrombocytopenia</span><span class="headingEndMark"> — </span>A risk of TPO receptor agonists in ITP patients comes from abruptly stopping treatment. An unfortunate aspect of product labeling [<a href="#rid169">169</a>] for TPO receptor agonists in ITP is the recommendation that they be held if the platelet count rises over 400,000/microL; this is based on no identified risk but was part of the dosing algorithm of the initial clinical trials. Given the very short platelet life-span, stopping the drug results in a rapid decrease in platelet count; platelet counts may often drop from &gt;400,000/microL to less than 5000/microL in less than one week. Rebound thrombocytopenia (defined as the platelet count dropping 10,000/microL below the prior baseline) was seen in approximately 10 percent of clinical trial patients [<a href="#rid20">20</a>].</p><p class="headingAnchor" id="H4016840"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>TPO</strong> – A number of thrombopoietin (TPO) molecules have been developed; they define a new and growing family of molecules called the thrombopoietin (c-mpl ligand) family, based upon their common ability to bind and activate the TPO receptor, c-mpl (<a class="graphic graphic_table graphicRef55953" href="/d/graphic/55953.html" rel="external">table 1</a>). (See <a class="local">'Thrombopoietins (c-mpl ligands)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical uses</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>ITP</strong> – TPO receptor agonists (TPO-RAs) available for use in immune thrombocytopenia (ITP) are <a class="drug drug_general" data-topicid="9493" href="/d/drug information/9493.html" rel="external">romiplostim</a>, <a class="drug drug_general" data-topicid="9051" href="/d/drug information/9051.html" rel="external">eltrombopag</a>, <a class="drug drug_general" data-topicid="117929" href="/d/drug information/117929.html" rel="external">avatrombopag</a>, and, in China, hetrombopag. (See  <a class="medical medical_review" href="/d/html/6678.html" rel="external">"Second-line and subsequent therapies for immune thrombocytopenia (ITP) in adults", section on 'TPO receptor agonists'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Aplastic anemia</strong> – <a class="drug drug_general" data-topicid="9051" href="/d/drug information/9051.html" rel="external">Eltrombopag</a> and <a class="drug drug_general" data-topicid="9493" href="/d/drug information/9493.html" rel="external">romiplostim</a> (Japan only) are approved for use in patients with aplastic anemia for whom immunosuppressive therapy has failed or as initial therapy when combined with immunosuppression. (See  <a class="medical medical_review" href="/d/html/7158.html" rel="external">"Treatment of aplastic anemia in adults"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Liver disease</strong> – <a class="drug drug_general" data-topicid="117929" href="/d/drug information/117929.html" rel="external">Avatrombopag</a> and <a class="drug drug_general" data-topicid="118602" href="/d/drug information/118602.html" rel="external">lusutrombopag</a> are non-peptide TPO receptor agonists approved for use in thrombocytopenic patients with liver disease undergoing an invasive procedure. (See  <a class="medical medical_review" href="/d/html/13932.html" rel="external">"Hemostatic abnormalities in patients with liver disease", section on 'Invasive procedures'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other disorders</strong> – TPO receptor agonists are under evaluation for a wide range of other thrombocytopenic disorders, including those associated with chemotherapy, surgery, and myelodysplastic syndromes. (See <a class="local">'Use of TPO receptor agonists'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – Side effects of TPO receptor agonists include thrombocytosis, possibly thrombosis, bone marrow reticulin fibrosis, and rebound thrombocytopenia. Hepatotoxicity has been reported with <a class="drug drug_general" data-topicid="9051" href="/d/drug information/9051.html" rel="external">eltrombopag</a>. Cost may also be an issue in some settings. (See <a class="local">'Side effects and risks'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Kuter DJ. The biology of thrombopoietin and thrombopoietin receptor agonists. Int J Hematol 2013; 98:10.</a></li><li><a class="nounderline abstract_t">Kuter DJ. Milestones in understanding platelet production: a historical overview. Br J Haematol 2014; 165:248.</a></li><li><a class="nounderline abstract_t">Sheridan WP, Kuter DJ. Mechanism of action and clinical trials of Mpl ligand. Curr Opin Hematol 1997; 4:312.</a></li><li><a class="nounderline abstract_t">Kuter DJ. New thrombopoietic growth factors. Clin Lymphoma Myeloma 2009; 9 Suppl 3:S347.</a></li><li><a class="nounderline abstract_t">Kuter DJ. New thrombopoietic growth factors. Blood 2007; 109:4607.</a></li><li><a class="nounderline abstract_t">Katsube T, Ishibashi T, Kano T, Wajima T. Population Pharmacokinetic and Pharmacodynamic Modeling of Lusutrombopag, a Newly Developed Oral Thrombopoietin Receptor Agonist, in Healthy Subjects. Clin Pharmacokinet 2016; 55:1423.</a></li><li><a class="nounderline abstract_t">Kim ES. Lusutrombopag: First Global Approval. Drugs 2016; 76:155.</a></li><li><a class="nounderline abstract_t">Terrault N, Chen YC, Izumi N, et al. Avatrombopag Before Procedures Reduces Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia. Gastroenterology 2018; 155:705.</a></li><li><a class="nounderline abstract_t">Xu Y, Song X, Du F, et al. A Randomized Controlled Study of rhTPO and rhIL-11 for the Prophylactic Treatment of Chemotherapy-Induced Thrombocytopenia in Non-Small Cell Lung Cancer. J Cancer 2018; 9:4718.</a></li><li><a class="nounderline abstract_t">Molineux G. The development of romiplostim for patients with immune thrombocytopenia. Ann N Y Acad Sci 2011; 1222:55.</a></li><li><a class="nounderline abstract_t">Basser RL, Begley CG. Thrombopoietin. Cancer Invest 2001; 19:660.</a></li><li><a class="nounderline abstract_t">Li J, Yang C, Xia Y, et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001; 98:3241.</a></li><li><a class="nounderline abstract_t">Basser RL, O'Flaherty E, Green M, et al. Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor. Blood 2002; 99:2599.</a></li><li><a class="nounderline abstract_t">Kuter DJ. Thrombopoietin and thrombopoietin mimetics in the treatment of thrombocytopenia. Annu Rev Med 2009; 60:193.</a></li><li><a class="nounderline abstract_t">Vadhan-Raj S, Murray LJ, Bueso-Ramos C, et al. Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer. Ann Intern Med 1997; 126:673.</a></li><li><a class="nounderline abstract_t">Harker LA, Marzec UM, Hunt P, et al. Dose-response effects of pegylated human megakaryocyte growth and development factor on platelet production and function in nonhuman primates. Blood 1996; 88:511.</a></li><li><a class="nounderline abstract_t">Cwirla SE, Balasubramanian P, Duffin DJ, et al. Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine. Science 1997; 276:1696.</a></li><li><a class="nounderline abstract_t">Wang B, Nichol JL, Sullivan JT. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther 2004; 76:628.</a></li><li><a class="nounderline abstract_t">Broudy VC, Lin NL. AMG531 stimulates megakaryopoiesis in vitro by binding to Mpl. Cytokine 2004; 25:52.</a></li><li><a class="nounderline abstract_t">Bussel JB, Kuter DJ, George JN, et al. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med 2006; 355:1672.</a></li><li><a class="nounderline abstract_t">Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 2008; 371:395.</a></li><li><a class="nounderline abstract_t">Kuter DJ, Rummel M, Boccia R, et al. Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med 2010; 363:1889.</a></li><li><a class="nounderline abstract_t">Kuter DJ, Bussel JB, Newland A, et al. Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. Br J Haematol 2013; 161:411.</a></li><li><a class="nounderline abstract_t">Sekeres MA, Kantarjian H, Fenaux P, et al. Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes. Cancer 2011; 117:992.</a></li><li><a class="nounderline abstract_t">Kantarjian H, Fenaux P, Sekeres MA, et al. Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. J Clin Oncol 2010; 28:437.</a></li><li><a class="nounderline abstract_t">Kantarjian HM, Giles FJ, Greenberg PL, et al. Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy. Blood 2010; 116:3163.</a></li><li><a class="nounderline abstract_t">Al-Samkari H, Marshall AL, Goodarzi K, Kuter DJ. The use of romiplostim in treating chemotherapy-induced thrombocytopenia in patients with solid tumors. Haematologica 2018; 103:e169.</a></li><li><a class="nounderline abstract_t">Soff GA, Miao Y, Bendheim G, et al. Romiplostim Treatment of Chemotherapy-Induced Thrombocytopenia. J Clin Oncol 2019; 37:2892.</a></li><li><a class="nounderline abstract_t">Al-Samkari H, Marshall AL, Goodarzi K, Kuter DJ. Romiplostim for the management of perioperative thrombocytopenia. Br J Haematol 2018; 182:106.</a></li><li><a class="nounderline abstract_t">Lee JW, Lee SE, Jung CW, et al. Romiplostim in patients with refractory aplastic anaemia previously treated with immunosuppressive therapy: a dose-finding and long-term treatment phase 2 trial. Lancet Haematol 2019; 6:e562.</a></li><li><a class="nounderline abstract_t">Duffy KJ, Price AT, Delorme E, et al. Identification of a pharmacophore for thrombopoietic activity of small, non-peptidyl molecules. 2. Rational design of naphtho[1,2-d]imidazole thrombopoietin mimics. J Med Chem 2002; 45:3576.</a></li><li><a class="nounderline abstract_t">Duffy KJ, Darcy MG, Delorme E, et al. Hydrazinonaphthalene and azonaphthalene thrombopoietin mimics are nonpeptidyl promoters of megakaryocytopoiesis. J Med Chem 2001; 44:3730.</a></li><li><a class="nounderline abstract_t">Duffy KJ, Shaw AN, Delorme E, et al. Identification of a pharmacophore for thrombopoietic activity of small, non-peptidyl molecules. 1. Discovery and optimization of salicylaldehyde thiosemicarbazone thrombopoietin mimics. J Med Chem 2002; 45:3573.</a></li><li class="breakAll">Duffy KJ, Erickson-Miller C. The discovery of eltrombopag, an orally bioavailable TpoR agonist. In: Target Validation in Drug Discovery, 1 ed, Academic Press, Burlington 2007. p.241.</li><li><a class="nounderline abstract_t">Erickson-Miller CL, DeLorme E, Tian SS, et al. Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist. Exp Hematol 2005; 33:85.</a></li><li><a class="nounderline abstract_t">Jenkins JM, Williams D, Deng Y, et al. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood 2007; 109:4739.</a></li><li><a class="nounderline abstract_t">Bussel JB, Provan D, Shamsi T, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet 2009; 373:641.</a></li><li><a class="nounderline abstract_t">Cheng G, Saleh MN, Marcher C, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet 2011; 377:393.</a></li><li><a class="nounderline abstract_t">Bussel JB, Cheng G, Saleh MN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007; 357:2237.</a></li><li><a class="nounderline abstract_t">Saleh MN, Bussel JB, Cheng G, et al. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood 2013; 121:537.</a></li><li><a class="nounderline abstract_t">McHutchison JG, Dusheiko G, Shiffman ML, et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med 2007; 357:2227.</a></li><li><a class="nounderline abstract_t">Desmond R, Townsley DM, Dumitriu B, et al. Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. Blood 2014; 123:1818.</a></li><li><a class="nounderline abstract_t">Olnes MJ, Scheinberg P, Calvo KR, et al. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med 2012; 367:11.</a></li><li><a class="nounderline abstract_t">Winer ES, Safran H, Karaszewska B, et al. Eltrombopag for thrombocytopenia in patients with advanced solid tumors receiving gemcitabine-based chemotherapy: a randomized, placebo-controlled phase 2 study. Int J Hematol 2017; 106:765.</a></li><li><a class="nounderline abstract_t">Kuter DJ, Allen LF. Avatrombopag, an oral thrombopoietin receptor agonist: results of two double-blind, dose-rising, placebo-controlled Phase 1 studies. Br J Haematol 2018; 183:466.</a></li><li><a class="nounderline abstract_t">Nomoto M, Ferry J, Hussein Z. Population Pharmacokinetic/Pharmacodynamic Analyses of Avatrombopag in Patients With Chronic Liver Disease and Optimal Dose Adjustment Guide With Concomitantly Administered CYP3A and CYP2C9 Inhibitors. J Clin Pharmacol 2018; 58:1629.</a></li><li><a class="nounderline abstract_t">Nomoto M, Pastino G, Rege B, et al. Pharmacokinetics, Pharmacodynamics, Pharmacogenomics, Safety, and Tolerability of Avatrombopag in Healthy Japanese and White Subjects. Clin Pharmacol Drug Dev 2018; 7:188.</a></li><li><a class="nounderline abstract_t">Nomoto M, Zamora CA, Schuck E, et al. Pharmacokinetic/pharmacodynamic drug-drug interactions of avatrombopag when coadministered with dual or selective CYP2C9 and CYP3A interacting drugs. Br J Clin Pharmacol 2018; 84:952.</a></li><li><a class="nounderline abstract_t">Terrault NA, Hassanein T, Howell CD, et al. Phase II study of avatrombopag in thrombocytopenic patients with cirrhosis undergoing an elective procedure. J Hepatol 2014; 61:1253.</a></li><li><a class="nounderline abstract_t">Bussel JB, Kuter DJ, Aledort LM, et al. A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia. Blood 2014; 123:3887.</a></li><li><a class="nounderline abstract_t">Jurczak W, Chojnowski K, Mayer J, et al. Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia. Br J Haematol 2018; 183:479.</a></li><li><a class="nounderline abstract_t">Syed YY. Hetrombopag: First Approval. Drugs 2021; 81:1581.</a></li><li><a class="nounderline abstract_t">Teramura M, Kobayashi S, Yoshinaga K, et al. Effect of thrombopoietin (c-Mpl ligand) alone and in combination with other hematopoietic growth factors on human megakaryocytopoiesis in serum-free cultures. Int J Hematol 1997; 66:373.</a></li><li><a class="nounderline abstract_t">Teramura M, Kobayashi S, Yoshinaga K, et al. Effect of interleukin 11 on normal and pathological thrombopoiesis. Cancer Chemother Pharmacol 1996; 38 Suppl:S99.</a></li><li><a class="nounderline abstract_t">Tsimberidou AM, Giles FJ, Khouri I, et al. Low-dose interleukin-11 in patients with bone marrow failure: update of the M. D. Anderson Cancer Center experience. Ann Oncol 2005; 16:139.</a></li><li><a class="nounderline abstract_t">Aribi A, Kantarjian H, Koller C, et al. The effect of interleukin 11 on thrombocytopenia associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. Cancer 2008; 113:1338.</a></li><li><a class="nounderline abstract_t">Tepler I, Elias L, Smith JW 2nd, et al. A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood 1996; 87:3607.</a></li><li><a class="nounderline abstract_t">Isaacs C, Robert NJ, Bailey FA, et al. Randomized placebo-controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin. J Clin Oncol 1997; 15:3368.</a></li><li><a class="nounderline abstract_t">Kizaki M, Miyakawa Y, Ikeda Y. Long-term administration of pegylated recombinant human megakaryocyte growth and development factor dramatically improved cytopenias in a patient with myelodysplastic syndrome. Br J Haematol 2003; 122:764.</a></li><li class="breakAll">Kaye JA. FDA Licensure of NEUMEGA to prevent severe chemotherapy-induced thrombocytopenia. In: Thrombopoietin: From Molecule to Medicine, Murphy MJ, Kuter DJ (Eds), AlphaMed Press, Miamisburg 1998. p.207.</li><li><a class="nounderline abstract_t">Robb L, Li R, Hartley L, et al. Infertility in female mice lacking the receptor for interleukin 11 is due to a defective uterine response to implantation. Nat Med 1998; 4:303.</a></li><li><a class="nounderline abstract_t">Nandurkar HH, Robb L, Tarlinton D, et al. Adult mice with targeted mutation of the interleukin-11 receptor (IL11Ra) display normal hematopoiesis. Blood 1997; 90:2148.</a></li><li><a class="nounderline abstract_t">Kuter DJ, Begley CG. Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. Blood 2002; 100:3457.</a></li><li class="breakAll">Kuter D. General aspects of thrombocytopenia, platelet transfusions, and thrombopoietic growth factors. In: Consultative Hemostasis and Thrombosis, 4th ed, Kitchens CKC, Konkle B (Eds), Elsevier Saunders, Philadelphia 2018. p.108.</li><li class="breakAll">Kuter DJ. Thrombopoietin Receptor Agonists. In: Platelets, 4th ed, Michelson A, Cattaneo M, Frelinger A, Newman P (Eds), Elsevier Bosby, 2019. p.1085.</li><li><a class="nounderline abstract_t">Nichol JL. Thrombopoietin levels after chemotherapy and in naturally occurring human diseases. Curr Opin Hematol 1998; 5:203.</a></li><li><a class="nounderline abstract_t">Emmons RV, Reid DM, Cohen RL, et al. Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction. Blood 1996; 87:4068.</a></li><li><a class="nounderline abstract_t">McMillan R, Wang L, Tomer A, et al. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood 2004; 103:1364.</a></li><li><a class="nounderline abstract_t">Ballem PJ, Segal GM, Stratton JR, et al. Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura. Evidence of both impaired platelet production and increased platelet clearance. J Clin Invest 1987; 80:33.</a></li><li><a class="nounderline abstract_t">Kuter DJ, Bussel J, Newland A, et al. Long-term treatment with romiplostim in patients with chronic immune thrombocytopenic purpura (ITP): 3-year update from an open-label extension study. Blood 2008; 112:154a.</a></li><li><a class="nounderline abstract_t">Bussel JB, Kuter DJ, Pullarkat V, et al. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood 2009; 113:2161.</a></li><li><a class="nounderline abstract_t">Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv 2019; 3:3829.</a></li><li><a class="nounderline abstract_t">Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv 2019; 3:3780.</a></li><li><a class="nounderline abstract_t">Martin TG 3rd, Somberg KA, Meng YG, et al. Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation. Ann Intern Med 1997; 127:285.</a></li><li><a class="nounderline abstract_t">Peck-Radosavljevic M, Wichlas M, Zacherl J, et al. Thrombopoietin induces rapid resolution of thrombocytopenia after orthotopic liver transplantation through increased platelet production. Blood 2000; 95:795.</a></li><li><a class="nounderline abstract_t">Afdhal NH, Dusheiko GM, Giannini EG, et al. Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy. Gastroenterology 2014; 146:442.</a></li><li><a class="nounderline abstract_t">Afdhal NH, Giannini EG, Tayyab G, et al. Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia. N Engl J Med 2012; 367:716.</a></li><li><a class="nounderline abstract_t">Makar RS, Zhukov OS, Sahud MA, Kuter DJ. Thrombopoietin levels in patients with disorders of platelet production: diagnostic potential and utility in predicting response to TPO receptor agonists. Am J Hematol 2013; 88:1041.</a></li><li><a class="nounderline abstract_t">Alvarado LJ, Huntsman HD, Cheng H, et al. Eltrombopag maintains human hematopoietic stem and progenitor cells under inflammatory conditions mediated by IFN-γ. Blood 2019; 133:2043.</a></li><li><a class="nounderline abstract_t">Townsley DM, Scheinberg P, Winkler T, et al. Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia. N Engl J Med 2017; 376:1540.</a></li><li><a class="nounderline abstract_t">Will B, Kawahara M, Luciano JP, et al. Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome. Blood 2009; 114:3899.</a></li><li><a class="nounderline abstract_t">Komatsu N, Okamoto T, Yoshida T, et al. Pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) increased platelet counts (plt) in patients with aplastic anemia (AA) and myelodysplastic syndrome (MDS) (abstract). Blood 2000; 96:296a.</a></li><li><a class="nounderline abstract_t">Giagounidis A, Mufti GJ, Fenaux P, et al. Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia. Cancer 2014; 120:1838.</a></li><li><a class="nounderline abstract_t">Roth M, Will B, Simkin G, et al. Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation. Blood 2012; 120:386.</a></li><li><a class="nounderline abstract_t">Platzbecker U, Wong RS, Verma A, et al. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial. Lancet Haematol 2015; 2:e417.</a></li><li class="breakAll">Version 1.2020 https://www.nccn.org/professionals/physician_gls/pdf/mds.pdf (Accessed on January 24, 2020).</li><li><a class="nounderline abstract_t">Balduini CL, Pecci A, Savoia A. Recent advances in the understanding and management of MYH9-related inherited thrombocytopenias. Br J Haematol 2011; 154:161.</a></li><li><a class="nounderline abstract_t">Pecci A, Gresele P, Klersy C, et al. Eltrombopag for the treatment of the inherited thrombocytopenia deriving from MYH9 mutations. Blood 2010; 116:5832.</a></li><li><a class="nounderline abstract_t">Harker LA, Carter RA, Marzec UM, et al. Correction of thrombocytopenia and ineffective platelet production in patients infected with human immunodeficiency virus (HIV) by PEG-rHuMGDF therapy (abstract). Blood 1998; 92:707a.</a></li><li><a class="nounderline abstract_t">Aslam MI, Cardile AP, Crawford GE. Use of peptide thrombopoietin receptor agonist romiplostim (Nplate) in a case of primary HIV-associated thrombocytopenia. J Int Assoc Provid AIDS Care 2014; 13:22.</a></li><li><a class="nounderline abstract_t">Vijayakrishnan R, Dani S, Ramasubramanian A, et al. Resistant thrombocytopenia in an HIV and hepatitis C patient: treatment response with novel agent eltrombopag. Clin Pract 2011; 1:e5.</a></li><li><a class="nounderline abstract_t">Kuter DJ. Managing thrombocytopenia associated with cancer chemotherapy. Oncology (Williston Park) 2015; 29:282.</a></li><li><a class="nounderline abstract_t">Hokom MM, Lacey D, Kinstler OB, et al. Pegylated megakaryocyte growth and development factor abrogates the lethal thrombocytopenia associated with carboplatin and irradiation in mice. Blood 1995; 86:4486.</a></li><li><a class="nounderline abstract_t">Columbyova L, Loda M, Scadden DT. Thrombopoietin receptor expression in human cancer cell lines and primary tissues. Cancer Res 1995; 55:3509.</a></li><li><a class="nounderline abstract_t">Erickson-Miller CL, Pillarisetti K, Kirchner J, et al. Low or undetectable TPO receptor expression in malignant tissue and cell lines derived from breast, lung, and ovarian tumors. BMC Cancer 2012; 12:405.</a></li><li><a class="nounderline abstract_t">Fanucchi M, Glaspy J, Crawford J, et al. Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. N Engl J Med 1997; 336:404.</a></li><li><a class="nounderline abstract_t">Basser RL, Rasko JE, Clarke K, et al. Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer. Blood 1997; 89:3118.</a></li><li><a class="nounderline abstract_t">Vadhan-Raj S, Verschraegen CF, Bueso-Ramos C, et al. Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer. Ann Intern Med 2000; 132:364.</a></li><li><a class="nounderline abstract_t">Moskowitz CH, Hamlin PA, Gabrilove J, et al. Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphoma. Ann Oncol 2007; 18:1842.</a></li><li><a class="nounderline abstract_t">Zhang X, Chuai Y, Nie W, et al. Thrombopoietin receptor agonists for prevention and treatment of chemotherapy-induced thrombocytopenia in patients with solid tumours. Cochrane Database Syst Rev 2017; 11:CD012035.</a></li><li><a class="nounderline abstract_t">Winer ES, Safran H, Karaszewska B, et al. Eltrombopag with gemcitabine-based chemotherapy in patients with advanced solid tumors: a randomized phase I study. Cancer Med 2015; 4:16.</a></li><li><a class="nounderline abstract_t">Kellum A, Jagiello-Gruszfeld A, Bondarenko IN, et al. A randomized, double-blind, placebo-controlled, dose ranging study to assess the efficacy and safety of eltrombopag in patients receiving carboplatin/paclitaxel for advanced solid tumors. Curr Med Res Opin 2010; 26:2339.</a></li><li><a class="nounderline abstract_t">Parameswaran R, Lunning M, Mantha S, et al. Romiplostim for management of chemotherapy-induced thrombocytopenia. Support Care Cancer 2014; 22:1217.</a></li><li><a class="nounderline abstract_t">Al-Samkari H, Parnes AD, Goodarzi K, et al. A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies. Haematologica 2021; 106:1148.</a></li><li><a class="nounderline abstract_t">Schiffer CA, Miller K, Larson RA, et al. A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia. Blood 2000; 95:2530.</a></li><li><a class="nounderline abstract_t">Archimbaud E, Ottmann OG, Yin JA, et al. A randomized, double-blind, placebo-controlled study with pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) as an adjunct to chemotherapy for adults with de novo acute myeloid leukemia. Blood 1999; 94:3694.</a></li><li><a class="nounderline abstract_t">Kuter DJ. What is the potential for thrombopoietic agents in acute leukemia? Best Pract Res Clin Haematol 2011; 24:553.</a></li><li><a class="nounderline abstract_t">Kuter DJ. What is the role of novel thrombopoietic agents in the management of acute leukemia? Best Pract Res Clin Haematol 2016; 29:372.</a></li><li><a class="nounderline abstract_t">Geissler K, Yin JA, Ganser A, et al. Prior and concurrent administration of recombinant human megakaryocyte growth and development factor in patients receiving consolidation chemotherapy for de novo acute myeloid leukemia--a randomized, placebo-controlled, double-blind safety and efficacy study. Ann Hematol 2003; 82:677.</a></li><li><a class="nounderline abstract_t">Frey N, Jang JH, Szer J, et al. Eltrombopag treatment during induction chemotherapy for acute myeloid leukaemia: a randomised, double-blind, phase 2 study. Lancet Haematol 2019; 6:e122.</a></li><li><a class="nounderline abstract_t">Fibbe WE, Heemskerk DP, Laterveer L, et al. Accelerated reconstitution of platelets and erythrocytes after syngeneic transplantation of bone marrow cells derived from thrombopoietin pretreated donor mice. Blood 1995; 86:3308.</a></li><li><a class="nounderline abstract_t">Somlo G, Sniecinski I, ter Veer A, et al. Recombinant human thrombopoietin in combination with granulocyte colony-stimulating factor enhances mobilization of peripheral blood progenitor cells, increases peripheral blood platelet concentration, and accelerates hematopoietic recovery following high-dose chemotherapy. Blood 1999; 93:2798.</a></li><li><a class="nounderline abstract_t">Nash RA, Kurzrock R, DiPersio J, et al. A phase I trial of recombinant human thrombopoietin in patients with delayed platelet recovery after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2000; 6:25.</a></li><li><a class="nounderline abstract_t">Schuster MW, Beveridge R, Frei-Lahr D, et al. The effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) on platelet recovery in breast cancer patients undergoing autologous bone marrow transplantation. Exp Hematol 2002; 30:1044.</a></li><li><a class="nounderline abstract_t">Glaspy J, Vredenburgh J, Demetri GD, et al. Effects of PEGylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) before high dose chemotherapy (HDC) with peripheral blood progenitor cell (PBPC) support (abstract). Blood 1997; 90:580a.</a></li><li><a class="nounderline abstract_t">Bento L, Bastida JM, García-Cadenas I, et al. Thrombopoietin Receptor Agonists for Severe Thrombocytopenia after Allogeneic Stem Cell Transplantation: Experience of the Spanish Group of Hematopoietic Stem Cell Transplant. Biol Blood Marrow Transplant 2019; 25:1825.</a></li><li><a class="nounderline abstract_t">Mahat U, Rotz SJ, Hanna R. Use of Thrombopoietin Receptor Agonists in Prolonged Thrombocytopenia after Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 2020; 26:e65.</a></li><li><a class="nounderline abstract_t">Marshall AL, Goodarzi K, Kuter DJ. Romiplostim in the management of the thrombocytopenic surgical patient. Transfusion 2015; 55:2505.</a></li><li><a class="nounderline abstract_t">Moussa MM, Mowafy N. Preoperative use of romiplostim in thrombocytopenic patients with chronic hepatitis C and liver cirrhosis. J Gastroenterol Hepatol 2013; 28:335.</a></li><li><a class="nounderline abstract_t">Arnold DM, Heddle NM, Cook RJ, et al. Perioperative oral eltrombopag versus intravenous immunoglobulin in patients with immune thrombocytopenia: a non-inferiority, multicentre, randomised trial. Lancet Haematol 2020; 7:e640.</a></li><li><a class="nounderline abstract_t">Kaushansky K. Thrombopoietin and the hematopoietic stem cell. Blood 1998; 92:1.</a></li><li><a class="nounderline abstract_t">Solar GP, Kerr WG, Zeigler FC, et al. Role of c-mpl in early hematopoiesis. Blood 1998; 92:4.</a></li><li><a class="nounderline abstract_t">Piacibello W, Sanavio F, Garetto L, et al. Extensive amplification and self-renewal of human primitive hematopoietic stem cells from cord blood. Blood 1997; 89:2644.</a></li><li><a class="nounderline abstract_t">Yagi M, Ritchie KA, Sitnicka E, et al. Sustained ex vivo expansion of hematopoietic stem cells mediated by thrombopoietin. Proc Natl Acad Sci U S A 1999; 96:8126.</a></li><li><a class="nounderline abstract_t">Thon JN, Italiano JE. Platelet formation. Semin Hematol 2010; 47:220.</a></li><li><a class="nounderline abstract_t">Choi ES, Nichol JL, Hokom MM, et al. Platelets generated in vitro from proplatelet-displaying human megakaryocytes are functional. Blood 1995; 85:402.</a></li><li><a class="nounderline abstract_t">Thon JN, Dykstra BJ, Beaulieu LM. Platelet bioreactor: accelerated evolution of design and manufacture. Platelets 2017; 28:472.</a></li><li><a class="nounderline abstract_t">Pallotta I, Lovett M, Kaplan DL, Balduini A. Three-dimensional system for the in vitro study of megakaryocytes and functional platelet production using silk-based vascular tubes. Tissue Eng Part C Methods 2011; 17:1223.</a></li><li><a class="nounderline abstract_t">Pallotta I, Kluge JA, Moreau J, et al. Characteristics of platelet gels combined with silk. Biomaterials 2014; 35:3678.</a></li><li><a class="nounderline abstract_t">Di Buduo CA, Wray LS, Tozzi L, et al. Programmable 3D silk bone marrow niche for platelet generation ex vivo and modeling of megakaryopoiesis pathologies. Blood 2015; 125:2254.</a></li><li><a class="nounderline abstract_t">Nakagawa Y, Nakamura S, Nakajima M, et al. Two differential flows in a bioreactor promoted platelet generation from human pluripotent stem cell-derived megakaryocytes. Exp Hematol 2013; 41:742.</a></li><li><a class="nounderline abstract_t">Martinez AF, McMahon RD, Horner M, Miller WM. A uniform-shear rate microfluidic bioreactor for real-time study of proplatelet formation and rapidly-released platelets. Biotechnol Prog 2017; 33:1614.</a></li><li><a class="nounderline abstract_t">Kuter DJ, Goodnough LT, Romo J, et al. Thrombopoietin therapy increases platelet yields in healthy platelet donors. Blood 2001; 98:1339.</a></li><li><a class="nounderline abstract_t">Goodnough LT, Kuter DJ, McCullough J, et al. Prophylactic platelet transfusions from healthy apheresis platelet donors undergoing treatment with thrombopoietin. Blood 2001; 98:1346.</a></li><li><a class="nounderline abstract_t">Vadhan-Raj S, Kavanagh JJ, Freedman RS, et al. Safety and efficacy of transfusions of autologous cryopreserved platelets derived from recombinant human thrombopoietin to support chemotherapy-associated severe thrombocytopenia: a randomised cross-over study. Lancet 2002; 359:2145.</a></li><li><a class="nounderline abstract_t">Ballmaier M, Schulze H, Strauss G, et al. Thrombopoietin in patients with congenital thrombocytopenia and absent radii: elevated serum levels, normal receptor expression, but defective reactivity to thrombopoietin. Blood 1997; 90:612.</a></li><li><a class="nounderline abstract_t">Ballmaier M, Germeshausen M, Schulze H, et al. c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia. Blood 2001; 97:139.</a></li><li><a class="nounderline abstract_t">van den Oudenrijn S, Bruin M, Folman CC, et al. Mutations in the thrombopoietin receptor, Mpl, in children with congenital amegakaryocytic thrombocytopenia. Br J Haematol 2000; 110:441.</a></li><li><a class="nounderline abstract_t">Bonsi L, Marchionni C, Alviano F, et al. Thrombocytopenia with absent radii (TAR) syndrome: from hemopoietic progenitor to mesenchymal stromal cell disease? Exp Hematol 2009; 37:1.</a></li><li><a class="nounderline abstract_t">Orita T, Tsunoda H, Yabuta N, et al. A novel therapeutic approach for thrombocytopenia by minibody agonist of the thrombopoietin receptor. Blood 2005; 105:562.</a></li><li><a class="nounderline abstract_t">Stefanich EG, Carlson-Zermeno CC, McEvoy K, et al. Dose schedule of recombinant murine thrombopoietin prior to myelosuppressive and myeloablative therapy in mice. Cancer Chemother Pharmacol 2001; 47:70.</a></li><li><a class="nounderline abstract_t">Neelis KJ, Visser TP, Dimjati W, et al. A single dose of thrombopoietin shortly after myelosuppressive total body irradiation prevents pancytopenia in mice by promoting short-term multilineage spleen-repopulating cells at the transient expense of bone marrow-repopulating cells. Blood 1998; 92:1586.</a></li><li><a class="nounderline abstract_t">Mouthon MA, Van der Meeren A, Gaugler MH, et al. Thrombopoietin promotes hematopoietic recovery and survival after high-dose whole body irradiation. Int J Radiat Oncol Biol Phys 1999; 43:867.</a></li><li><a class="nounderline abstract_t">Kaushansky K, Lin N, Grossmann A, et al. Thrombopoietin expands erythroid, granulocyte-macrophage, and megakaryocytic progenitor cells in normal and myelosuppressed mice. Exp Hematol 1996; 24:265.</a></li><li><a class="nounderline abstract_t">Kaushansky K. Thrombopoietin: more than a lineage-specific megakaryocyte growth factor. Stem Cells 1997; 15 Suppl 1:97.</a></li><li><a class="nounderline abstract_t">Neelis KJ, Hartong SC, Egeland T, et al. The efficacy of single-dose administration of thrombopoietin with coadministration of either granulocyte/macrophage or granulocyte colony-stimulating factor in myelosuppressed rhesus monkeys. Blood 1997; 90:2565.</a></li><li><a class="nounderline abstract_t">Neelis KJ, Qingliang L, Thomas GR, et al. Prevention of thrombocytopenia by thrombopoietin in myelosuppressed rhesus monkeys accompanied by prominent erythropoietic stimulation and iron depletion. Blood 1997; 90:58.</a></li><li><a class="nounderline abstract_t">Neelis KJ, Dubbelman YD, Qingliang L, et al. Simultaneous administration of TPO and G-CSF after cytoreductive treatment of rhesus monkeys prevents thrombocytopenia, accelerates platelet and red cell reconstitution, alleviates neutropenia, and promotes the recovery of immature bone marrow cells. Exp Hematol 1997; 25:1084.</a></li><li><a class="nounderline abstract_t">Liesveld JL, Phillips GL 2nd, Becker M, et al. A phase 1 trial of eltrombopag in patients undergoing stem cell transplantation after total body irradiation. Biol Blood Marrow Transplant 2013; 19:1745.</a></li><li class="breakAll">https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125268s168lbl.pdf (Accessed on March 30, 2021).</li><li><a class="nounderline abstract_t">Kuter DJ. Thrombopoietin: biology, clinical applications, role in the donor setting. J Clin Apher 1996; 11:149.</a></li><li><a class="nounderline abstract_t">Barger TE, Boshier A, Jawa V, et al. Assessment of romiplostim immunogenicity in adult patients in clinical trials and in a global registry. Blood 2018; 132 (Supplement 1):2427.</a></li><li><a class="nounderline abstract_t">Sarpatwari A, Bennett D, Logie JW, et al. Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research Database. Haematologica 2010; 95:1167.</a></li><li><a class="nounderline abstract_t">Severinsen MT, Engebjerg MC, Farkas DK, et al. Risk of venous thromboembolism in patients with primary chronic immune thrombocytopenia: a Danish population-based cohort study. Br J Haematol 2011; 152:360.</a></li><li><a class="nounderline abstract_t">Cines DB, Wasser J, Rodeghiero F, et al. Safety and efficacy of romiplostim in splenectomized and nonsplenectomized patients with primary immune thrombocytopenia. Haematologica 2017; 102:1342.</a></li><li><a class="nounderline abstract_t">Harker LA, Hunt P, Marzec UM, et al. Regulation of platelet production and function by megakaryocyte growth and development factor in nonhuman primates. Blood 1996; 87:1833.</a></li><li><a class="nounderline abstract_t">Harker LA. Platelets in thrombotic disorders: quantitative and qualitative platelet disorders predisposing to arterial thrombosis. Semin Hematol 1998; 35:241.</a></li><li><a class="nounderline abstract_t">Fontana V, Jy W, Ahn ER, et al. Increased procoagulant cell-derived microparticles (C-MP) in splenectomized patients with ITP. Thromb Res 2008; 122:599.</a></li><li><a class="nounderline abstract_t">Yan XQ, Lacey D, Fletcher F, et al. Chronic exposure to retroviral vector encoded MGDF (mpl-ligand) induces lineage-specific growth and differentiation of megakaryocytes in mice. Blood 1995; 86:4025.</a></li><li><a class="nounderline abstract_t">Frey BM, Rafii S, Teterson M, et al. Adenovector-mediated expression of human thrombopoietin cDNA in immune-compromised mice: insights into the pathophysiology of osteomyelofibrosis. J Immunol 1998; 160:691.</a></li><li><a class="nounderline abstract_t">Villeval JL, Cohen-Solal K, Tulliez M, et al. High thrombopoietin production by hematopoietic cells induces a fatal myeloproliferative syndrome in mice. Blood 1997; 90:4369.</a></li><li><a class="nounderline abstract_t">Yanagida M, Ide Y, Imai A, et al. The role of transforming growth factor-beta in PEG-rHuMGDF-induced reversible myelofibrosis in rats. Br J Haematol 1997; 99:739.</a></li><li><a class="nounderline abstract_t">Ulich TR, del Castillo J, Senaldi G, et al. Systemic hematologic effects of PEG-rHuMGDF-induced megakaryocyte hyperplasia in mice. Blood 1996; 87:5006.</a></li><li><a class="nounderline abstract_t">Douglas VK, Tallman MS, Cripe LD, Peterson LC. Thrombopoietin administered during induction chemotherapy to patients with acute myeloid leukemia induces transient morphologic changes that may resemble chronic myeloproliferative disorders. Am J Clin Pathol 2002; 117:844.</a></li><li><a class="nounderline abstract_t">Kuter DJ, Mufti GJ, Bain BJ, et al. Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim. Blood 2009; 114:3748.</a></li><li><a class="nounderline abstract_t">Brynes RK, Orazi A, Theodore D, et al. Evaluation of bone marrow reticulin in patients with chronic immune thrombocytopenia treated with eltrombopag: Data from the EXTEND study. Am J Hematol 2015; 90:598.</a></li><li><a class="nounderline abstract_t">Janssens A, Rodeghiero F, Anderson D, et al. Changes in bone marrow morphology in adults receiving romiplostim for the treatment of thrombocytopenia associated with primary immune thrombocytopenia. Ann Hematol 2016; 95:1077.</a></li><li><a class="nounderline abstract_t">Brynes RK, Wong RS, Thein MM, et al. A 2-Year, Longitudinal, Prospective Study of the Effects of Eltrombopag on Bone Marrow in Patients with Chronic Immune Thrombocytopenia. Acta Haematol 2017; 137:66.</a></li><li class="breakAll">http://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022291s021lbl.pdf#page=35 (Accessed on January 14, 2020).</li></ol></div><div id="topicVersionRevision">Topic 6671 Version 37.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23821332" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The biology of thrombopoietin and thrombopoietin receptor agonists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24528208" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Milestones in understanding platelet production: a historical overview.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9288463" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Mechanism of action and clinical trials of Mpl ligand.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19778863" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : New thrombopoietic growth factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17289815" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : New thrombopoietic growth factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27209291" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Population Pharmacokinetic and Pharmacodynamic Modeling of Lusutrombopag, a Newly Developed Oral Thrombopoietin Receptor Agonist, in Healthy Subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26666417" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Lusutrombopag: First Global Approval.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29778606" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Avatrombopag Before Procedures Reduces Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30588257" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : A Randomized Controlled Study of rhTPO and rhIL-11 for the Prophylactic Treatment of Chemotherapy-Induced Thrombocytopenia in Non-Small Cell Lung Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21434943" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The development of romiplostim for patients with immune thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11486709" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Thrombopoietin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11719360" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Thrombocytopenia caused by the development of antibodies to thrombopoietin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11895799" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19642221" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Thrombopoietin and thrombopoietin mimetics in the treatment of thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9139552" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8695799" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Dose-response effects of pegylated human megakaryocyte growth and development factor on platelet production and function in nonhuman primates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9180079" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15592334" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14693160" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : AMG531 stimulates megakaryopoiesis in vitro by binding to Mpl.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17050891" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18242413" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21067381" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Romiplostim or standard of care in patients with immune thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23432528" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20945323" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20008626" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20631375" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29242295" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : The use of romiplostim in treating chemotherapy-induced thrombocytopenia in patients with solid tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31545663" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Romiplostim Treatment of Chemotherapy-Induced Thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29767837" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Romiplostim for the management of perioperative thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31474546" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Romiplostim in patients with refractory aplastic anaemia previously treated with immunosuppressive therapy: a dose-finding and long-term treatment phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12166929" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Identification of a pharmacophore for thrombopoietic activity of small, non-peptidyl molecules. 2. Rational design of naphtho[1,2-d]imidazole thrombopoietin mimics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11606138" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Hydrazinonaphthalene and azonaphthalene thrombopoietin mimics are nonpeptidyl promoters of megakaryocytopoiesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12166928" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Identification of a pharmacophore for thrombopoietic activity of small, non-peptidyl molecules. 1. Discovery and optimization of salicylaldehyde thiosemicarbazone thrombopoietin mimics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12166928" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Identification of a pharmacophore for thrombopoietic activity of small, non-peptidyl molecules. 1. Discovery and optimization of salicylaldehyde thiosemicarbazone thrombopoietin mimics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15661401" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17327409" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19231632" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20739054" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18046028" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23169778" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18046027" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24345753" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22762314" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Eltrombopag and improved hematopoiesis in refractory aplastic anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28864871" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Eltrombopag for thrombocytopenia in patients with advanced solid tumors receiving gemcitabine-based chemotherapy: a randomized, placebo-controlled phase 2 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30203841" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Avatrombopag, an oral thrombopoietin receptor agonist: results of two double-blind, dose-rising, placebo-controlled Phase 1 studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29905956" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Population Pharmacokinetic/Pharmacodynamic Analyses of Avatrombopag in Patients With Chronic Liver Disease and Optimal Dose Adjustment Guide With Concomitantly Administered CYP3A and CYP2C9 Inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28339166" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Pharmacokinetics, Pharmacodynamics, Pharmacogenomics, Safety, and Tolerability of Avatrombopag in Healthy Japanese and White Subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29341245" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Pharmacokinetic/pharmacodynamic drug-drug interactions of avatrombopag when coadministered with dual or selective CYP2C9 and CYP3A interacting drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25048952" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Phase II study of avatrombopag in thrombocytopenic patients with cirrhosis undergoing an elective procedure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24802775" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30191972" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34357499" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Hetrombopag: First Approval.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9401284" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Effect of thrombopoietin (c-Mpl ligand) alone and in combination with other hematopoietic growth factors on human megakaryocytopoiesis in serum-free cultures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8765427" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Effect of interleukin 11 on normal and pathological thrombopoiesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15598951" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Low-dose interleukin-11 in patients with bone marrow failure: update of the M. D. Anderson Cancer Center experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18629842" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : The effect of interleukin 11 on thrombocytopenia associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8611684" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9363868" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Randomized placebo-controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12930386" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Long-term administration of pegylated recombinant human megakaryocyte growth and development factor dramatically improved cytopenias in a patient with myelodysplastic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12930386" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Long-term administration of pegylated recombinant human megakaryocyte growth and development factor dramatically improved cytopenias in a patient with myelodysplastic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9500603" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Infertility in female mice lacking the receptor for interleukin 11 is due to a defective uterine response to implantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9310465" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Adult mice with targeted mutation of the interleukin-11 receptor (IL11Ra) display normal hematopoiesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12411315" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Recombinant human thrombopoietin: basic biology and evaluation of clinical studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12411315" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Recombinant human thrombopoietin: basic biology and evaluation of clinical studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12411315" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Recombinant human thrombopoietin: basic biology and evaluation of clinical studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9664161" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Thrombopoietin levels after chemotherapy and in naturally occurring human diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8639762" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14576051" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3597777" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura. Evidence of both impaired platelet production and increased platelet clearance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Long-term treatment with romiplostim in patients with chronic immune thrombocytopenic purpura (ITP): 3-year update from an open-label extension study</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18981291" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31794604" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : American Society of Hematology 2019 guidelines for immune thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31770441" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Updated international consensus report on the investigation and management of primary immune thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9265428" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10648388" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Thrombopoietin induces rapid resolution of thrombocytopenia after orthotopic liver transplantation through increased platelet production.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24126097" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22913681" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23913253" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Thrombopoietin levels in patients with disorders of platelet production: diagnostic potential and utility in predicting response to TPO receptor agonists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30803992" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Eltrombopag maintains human hematopoietic stem and progenitor cells under inflammatory conditions mediated by IFN-γ.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28423296" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19710504" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) increased platelet counts (plt) in patients with aplastic anemia (AA) and myelodysplastic syndrome (MDS) (abstract)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24706489" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22627766" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26686043" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26686043" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21542825" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Recent advances in the understanding and management of MYH9-related inherited thrombocytopenias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20844233" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Eltrombopag for the treatment of the inherited thrombocytopenia deriving from MYH9 mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Correction of thrombocytopenia and ineffective platelet production in patients infected with human immunodeficiency virus (HIV) by PEG-rHuMGDF therapy (abstract)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24036490" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Use of peptide thrombopoietin receptor agonist romiplostim (Nplate) in a case of primary HIV-associated thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24765278" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Resistant thrombocytopenia in an HIV and hepatitis C patient: treatment response with novel agent eltrombopag.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25952492" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Managing thrombocytopenia associated with cancer chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8541537" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Pegylated megakaryocyte growth and development factor abrogates the lethal thrombocytopenia associated with carboplatin and irradiation in mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7627956" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Thrombopoietin receptor expression in human cancer cell lines and primary tissues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22967017" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Low or undetectable TPO receptor expression in malignant tissue and cell lines derived from breast, lung, and ovarian tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9010146" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9129014" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10691586" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17872903" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29178132" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Thrombopoietin receptor agonists for prevention and treatment of chemotherapy-induced thrombocytopenia in patients with solid tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25165041" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Eltrombopag with gemcitabine-based chemotherapy in patients with advanced solid tumors: a randomized phase I study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20735290" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : A randomized, double-blind, placebo-controlled, dose ranging study to assess the efficacy and safety of eltrombopag in patients receiving carboplatin/paclitaxel for advanced solid tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24414994" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Romiplostim for management of chemotherapy-induced thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32499239" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10753831" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10572081" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : A randomized, double-blind, placebo-controlled study with pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) as an adjunct to chemotherapy for adults with de novo acute myeloid leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22127320" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : What is the potential for thrombopoietic agents in acute leukemia?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27890262" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : What is the role of novel thrombopoietic agents in the management of acute leukemia?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14530872" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Prior and concurrent administration of recombinant human megakaryocyte growth and development factor in patients receiving consolidation chemotherapy for de novo acute myeloid leukemia--a randomized, placebo-controlled, double-blind safety and efficacy study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30704923" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Eltrombopag treatment during induction chemotherapy for acute myeloid leukaemia: a randomised, double-blind, phase 2 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7579432" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Accelerated reconstitution of platelets and erythrocytes after syngeneic transplantation of bone marrow cells derived from thrombopoietin pretreated donor mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10216073" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Recombinant human thrombopoietin in combination with granulocyte colony-stimulating factor enhances mobilization of peripheral blood progenitor cells, increases peripheral blood platelet concentration, and accelerates hematopoietic recovery following high-dose chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10707996" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : A phase I trial of recombinant human thrombopoietin in patients with delayed platelet recovery after hematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12225796" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : The effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) on platelet recovery in breast cancer patients undergoing autologous bone marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Effects of PEGylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) before high dose chemotherapy (HDC) with peripheral blood progenitor cell (PBPC) support (abstract)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31152794" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Thrombopoietin Receptor Agonists for Severe Thrombocytopenia after Allogeneic Stem Cell Transplantation: Experience of the Spanish Group of Hematopoietic Stem Cell Transplant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31830528" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Use of Thrombopoietin Receptor Agonists in Prolonged Thrombocytopenia after Hematopoietic Stem Cell Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26033367" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Romiplostim in the management of the thrombocytopenic surgical patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22849409" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Preoperative use of romiplostim in thrombocytopenic patients with chronic hepatitis C and liver cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32853584" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Perioperative oral eltrombopag versus intravenous immunoglobulin in patients with immune thrombocytopenia: a non-inferiority, multicentre, randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9639491" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Thrombopoietin and the hematopoietic stem cell.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9639492" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Role of c-mpl in early hematopoiesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9108381" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Extensive amplification and self-renewal of human primitive hematopoietic stem cells from cord blood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10393959" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Sustained ex vivo expansion of hematopoietic stem cells mediated by thrombopoietin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20620432" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Platelet formation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7529062" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Platelets generated in vitro from proplatelet-displaying human megakaryocytes are functional.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28112988" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Platelet bioreactor: accelerated evolution of design and manufacture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21895494" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Three-dimensional system for the in vitro study of megakaryocytes and functional platelet production using silk-based vascular tubes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24480538" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Characteristics of platelet gels combined with silk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25575540" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Programmable 3D silk bone marrow niche for platelet generation ex vivo and modeling of megakaryopoiesis pathologies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23618622" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Two differential flows in a bioreactor promoted platelet generation from human pluripotent stem cell-derived megakaryocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28960897" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : A uniform-shear rate microfluidic bioreactor for real-time study of proplatelet formation and rapidly-released platelets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11520780" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Thrombopoietin therapy increases platelet yields in healthy platelet donors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11520781" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Prophylactic platelet transfusions from healthy apheresis platelet donors undergoing treatment with thrombopoietin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12090979" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Safety and efficacy of transfusions of autologous cryopreserved platelets derived from recombinant human thrombopoietin to support chemotherapy-associated severe thrombocytopenia: a randomised cross-over study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9226161" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Thrombopoietin in patients with congenital thrombocytopenia and absent radii: elevated serum levels, normal receptor expression, but defective reactivity to thrombopoietin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11133753" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10971406" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Mutations in the thrombopoietin receptor, Mpl, in children with congenital amegakaryocytic thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19028006" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Thrombocytopenia with absent radii (TAR) syndrome: from hemopoietic progenitor to mesenchymal stromal cell disease?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15374889" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : A novel therapeutic approach for thrombocytopenia by minibody agonist of the thrombopoietin receptor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11221965" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Dose schedule of recombinant murine thrombopoietin prior to myelosuppressive and myeloablative therapy in mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9716586" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : A single dose of thrombopoietin shortly after myelosuppressive total body irradiation prevents pancytopenia in mice by promoting short-term multilineage spleen-repopulating cells at the transient expense of bone marrow-repopulating cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10098443" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Thrombopoietin promotes hematopoietic recovery and survival after high-dose whole body irradiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8641351" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Thrombopoietin expands erythroid, granulocyte-macrophage, and megakaryocytic progenitor cells in normal and myelosuppressed mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9368329" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Thrombopoietin: more than a lineage-specific megakaryocyte growth factor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9326222" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : The efficacy of single-dose administration of thrombopoietin with coadministration of either granulocyte/macrophage or granulocyte colony-stimulating factor in myelosuppressed rhesus monkeys.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9207438" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Prevention of thrombocytopenia by thrombopoietin in myelosuppressed rhesus monkeys accompanied by prominent erythropoietic stimulation and iron depletion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9293906" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Simultaneous administration of TPO and G-CSF after cytoreductive treatment of rhesus monkeys prevents thrombocytopenia, accelerates platelet and red cell reconstitution, alleviates neutropenia, and promotes the recovery of immature bone marrow cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24120380" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : A phase 1 trial of eltrombopag in patients undergoing stem cell transplantation after total body irradiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24120380" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : A phase 1 trial of eltrombopag in patients undergoing stem cell transplantation after total body irradiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8915820" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Thrombopoietin: biology, clinical applications, role in the donor setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Assessment of romiplostim immunogenicity in adult patients in clinical trials and in a global registry</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20145266" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research Database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20955411" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : Risk of venous thromboembolism in patients with primary chronic immune thrombocytopenia: a Danish population-based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28411254" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : Safety and efficacy of romiplostim in splenectomized and nonsplenectomized patients with primary immune thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8634430" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : Regulation of platelet production and function by megakaryocyte growth and development factor in nonhuman primates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9685170" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : Platelets in thrombotic disorders: quantitative and qualitative platelet disorders predisposing to arterial thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18334267" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : Increased procoagulant cell-derived microparticles (C-MP) in splenectomized patients with ITP.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7492757" id="rid158" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>159 : Chronic exposure to retroviral vector encoded MGDF (mpl-ligand) induces lineage-specific growth and differentiation of megakaryocytes in mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9551904" id="rid159" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>160 : Adenovector-mediated expression of human thrombopoietin cDNA in immune-compromised mice: insights into the pathophysiology of osteomyelofibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9373248" id="rid160" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>161 : High thrombopoietin production by hematopoietic cells induces a fatal myeloproliferative syndrome in mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9432016" id="rid161" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>162 : The role of transforming growth factor-beta in PEG-rHuMGDF-induced reversible myelofibrosis in rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8652813" id="rid162" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>163 : Systemic hematologic effects of PEG-rHuMGDF-induced megakaryocyte hyperplasia in mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12047134" id="rid163" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>164 : Thrombopoietin administered during induction chemotherapy to patients with acute myeloid leukemia induces transient morphologic changes that may resemble chronic myeloproliferative disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19671919" id="rid164" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>165 : Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25801698" id="rid165" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>166 : Evaluation of bone marrow reticulin in patients with chronic immune thrombocytopenia treated with eltrombopag: Data from the EXTEND study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27130310" id="rid166" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>167 : Changes in bone marrow morphology in adults receiving romiplostim for the treatment of thrombocytopenia associated with primary immune thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28006767" id="rid167" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>168 : A 2-Year, Longitudinal, Prospective Study of the Effects of Eltrombopag on Bone Marrow in Patients with Chronic Immune Thrombocytopenia.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
